<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>NULOJIX- belatacept injection, powder, lyophilized, for solution </strong><br>E.R. Squibb &amp; Sons, L.L.C.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use NULOJIX safely and effectively. See full prescribing information for NULOJIX.<br><br>NULOJIX (belatacept) for injection, for intravenous use<br>Initial U.S. Approval: 2011</div>
<div class="Warning"><div>
<h1 class="Warning">WARNING: POST-TRANSPLANT <span class="product-label-link" type="condition" conceptid="4079147" conceptname="Lymphoproliferative disorder">LYMPHOPROLIFERATIVE DISORDER</span>, OTHER MALIGNANCIES, AND SERIOUS <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">INFECTIONS</span></h1>
<h1 class="Warning"><span class="Bold"><span class="Italics">See full prescribing information for complete boxed warning.</span></span></h1>
<dl>
<dt>•</dt>
<dd><span class="Bold">Increased risk for developing post-transplant <span class="product-label-link" type="condition" conceptid="4079147" conceptname="Lymphoproliferative disorder">lymphoproliferative disorder</span> (PTLD), predominantly involving the central nervous system (CNS). Recipients without immunity to Epstein-Barr virus (EBV) are at a particularly increased risk; therefore, use in EBV seropositive patients only. Do not use NULOJIX in transplant recipients who are EBV seronegative or with unknown serostatus. <a href="#s4">(4</a>, <a href="#s5.1">5.1)</a></span></dd>
<dt>•</dt>
<dd><span class="Bold">Only physicians experienced in immunosuppressive therapy and management of kidney transplant patients should prescribe NULOJIX. <a href="#s5.2">(5.2)</a></span></dd>
<dt>•</dt>
<dd><span class="Bold">Increased susceptibility to <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> and the possible development of malignancies may result from <span class="product-label-link" type="condition" conceptid="4242843" conceptname="Immunosuppression">immunosuppression</span>. <a href="#s5.1">(5.1</a>, <a href="#s5.3">5.3</a>, <a href="#s5.4">5.4</a>, <a href="#s5.5">5.5)</a></span></dd>
<dt>•</dt>
<dd><span class="Bold">Use in liver transplant patients is not recommended due to an increased risk of graft loss and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. <a href="#s5.6">(5.6)</a></span></dd>
</dl>
</div></div>
<div></div>
<div class="Warning"><div>
<h1 class="Warning">WARNING: POST-TRANSPLANT <span class="product-label-link" type="condition" conceptid="4079147" conceptname="Lymphoproliferative disorder">LYMPHOPROLIFERATIVE DISORDER</span>, OTHER MALIGNANCIES, AND SERIOUS <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">INFECTIONS</span></h1>
<h1 class="Warning"><span class="Bold"><span class="Italics">See full prescribing information for complete boxed warning.</span></span></h1>
<dl>
<dt>•</dt>
<dd><span class="Bold">Increased risk for developing post-transplant <span class="product-label-link" type="condition" conceptid="4079147" conceptname="Lymphoproliferative disorder">lymphoproliferative disorder</span> (PTLD), predominantly involving the central nervous system (CNS). Recipients without immunity to Epstein-Barr virus (EBV) are at a particularly increased risk; therefore, use in EBV seropositive patients only. Do not use NULOJIX in transplant recipients who are EBV seronegative or with unknown serostatus. <a href="#s4">(4</a>, <a href="#s5.1">5.1)</a></span></dd>
<dt>•</dt>
<dd><span class="Bold">Only physicians experienced in immunosuppressive therapy and management of kidney transplant patients should prescribe NULOJIX. <a href="#s5.2">(5.2)</a></span></dd>
<dt>•</dt>
<dd><span class="Bold">Increased susceptibility to <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> and the possible development of malignancies may result from <span class="product-label-link" type="condition" conceptid="4242843" conceptname="Immunosuppression">immunosuppression</span>. <a href="#s5.1">(5.1</a>, <a href="#s5.3">5.3</a>, <a href="#s5.4">5.4</a>, <a href="#s5.5">5.5)</a></span></dd>
<dt>•</dt>
<dd><span class="Bold">Use in liver transplant patients is not recommended due to an increased risk of graft loss and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. <a href="#s5.6">(5.6)</a></span></dd>
</dl>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<dl>
<dt>•</dt>
<dd>NULOJIX is a selective T-cell costimulation blocker indicated for prophylaxis of organ rejection in adult patients receiving a kidney transplant. <a href="#s1.1">(1.1)</a>
</dd>
<dt>•</dt>
<dd>Use in combination with basiliximab induction, mycophenolate mofetil, and corticosteroids. <a href="#s1.1">(1.1)</a>
</dd>
</dl>
<p class="Highlighta"><span class="Italics">Limitations of Use</span>: </p>
<dl>
<dt>•</dt>
<dd>Use only in patients who are EBV seropositive. <a href="#s1.2">(1.2</a>, <a href="#s4">4</a>, <a href="#s5.1">5.1)</a>
</dd>
<dt>•</dt>
<dd>Use has not been established for the prophylaxis of organ rejection in transplanted organs other than the kidney. <a href="#s1.2">(1.2</a>, <a href="#s5.6">5.6)</a>
</dd>
</dl>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<dl>
<dt>•</dt>
<dd>Use of higher than recommended or more frequent dosing is not recommended due to increased risk of serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> and malignancy. <a href="#s5.1">(5.1</a>, <a href="#s5.4">5.4</a>, <a href="#s6.1">6.1)</a>
</dd>
<dt>•</dt>
<dd>For complete dosing instructions, see full prescribing information. <a href="#s2.1">(2.1)</a>
</dd>
</dl>
<table width="100%">
<caption><span>Dosing of NULOJIX for Kidney Transplant Recipients <a href="#s2.1">(2.1)</a></span></caption>
<col width="70%">
<col width="30%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Toprule"><p class="Highlighta"><span class="Bold">Dosing for Initial Phase</span> </p></td>
<td class="Botrule Toprule" align="center"><p class="Highlighta"><span class="Bold">Dose</span> </p></td>
</tr>
<tr>
<td><p class="Highlighta">   Day 1 (day of transplantation, prior to implantation) and Day 5 (approximately 96 hours after Day 1 dose) </p></td>
<td align="center"><p class="Highlighta">10 mg per kg </p></td>
</tr>
<tr>
<td><p class="Highlighta">   End of Week 2 and Week 4 after transplantation </p></td>
<td align="center"><p class="Highlighta">10 mg per kg </p></td>
</tr>
<tr>
<td class="Botrule"><p class="Highlighta">   End of Week 8 and Week 12 after transplantation </p></td>
<td class="Botrule" align="center"><p class="Highlighta">10 mg per kg </p></td>
</tr>
<tr>
<td class="Botrule Toprule"><p class="Highlighta"><span class="Bold">Dosing for Maintenance Phase</span> </p></td>
<td class="Botrule Toprule" align="center"><p class="Highlighta"><span class="Bold">Dose</span> </p></td>
</tr>
<tr class="Last">
<td class="Botrule Toprule"><p class="Highlighta">   End of Week 16 after transplantation and every 4 weeks (plus or minus 3 days) thereafter </p></td>
<td class="Botrule Toprule" align="center"><p class="Highlighta">5 mg per kg </p></td>
</tr>
</tbody>
</table>
<dl>
<dt>•</dt>
<dd>For intravenous infusion only; administer over 30 minutes. <a href="#s2.1">(2.1</a>, <a href="#s2.2">2.2)</a>
</dd>
<dt>•</dt>
<dd>Only use the enclosed <span class="Italics"><span class="Underline">silicone-free disposable syringe</span></span> to prepare for administration. <a href="#s2.2">(2.2)</a>
</dd>
</dl>
</div>
<div></div>
<div><div></div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><dl>
<dt>•</dt>
<dd>Lyophilized powder for injection: 250 mg per vial <a href="#s3">(3)</a>
</dd>
</dl></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd>Patients who are EBV seronegative or with unknown EBV serostatus. <a href="#s4">(4)</a>
</dd>
</dl></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd>
<span class="Italics">Post-Transplant <span class="product-label-link" type="condition" conceptid="4079147" conceptname="Lymphoproliferative disorder">Lymphoproliferative Disorder</span> (PTLD)</span>: increased risk, predominantly involving the CNS; monitor for new or worsening neurological, cognitive, or behavioral signs and symptoms. <a href="#s0">(Boxed Warning</a>, <a href="#s4">4</a>, <a href="#s5.1">5.1</a>, <a href="#s5.6">5.6)</a>
</dd>
<dt>•</dt>
<dd>
<span class="Italics">Other malignancies</span>: increased risk with all immunosuppressants; appears related to intensity and duration of use. Avoid prolonged exposure to UV light and sunlight. <a href="#s5.3">(5.3)</a>
</dd>
<dt>•</dt>
<dd>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="433957" conceptname="Progressive multifocal leukoencephalopathy">Progressive Multifocal Leukoencephalopathy</span> (PML)</span>: increased risk; consider in the diagnosis of patients reporting new or worsening neurological, cognitive, or behavioral signs and symptoms. Recommended doses of immunosuppressants should not be exceeded. <a href="#s5.4">(5.4)</a>
</dd>
<dt>•</dt>
<dd>
<span class="Italics">Other serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span></span>: increased risk of bacterial, viral, fungal, and protozoal <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, including <span class="product-label-link" type="condition" conceptid="4247535" conceptname="Opportunistic infectious disease">opportunistic infections</span> and <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span>. Some <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> were fatal. Polyoma virus-associated <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">nephropathy</span> can lead to kidney graft loss; consider reduction in <span class="product-label-link" type="condition" conceptid="4242843" conceptname="Immunosuppression">immunosuppression</span>. Evaluate for <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> and initiate treatment for latent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> prior to NULOJIX use. Cytomegalovirus and pneumocystis prophylaxis are recommended after transplantation. <a href="#s5.1">(5.1</a>, <a href="#s5.4">5.4</a>, <a href="#s5.5">5.5)</a>
</dd>
<dt>•</dt>
<dd>
<span class="Italics">Liver transplant</span>: use is not recommended. <a href="#s5.6">(5.6)</a>
</dd>
<dt>•</dt>
<dd>
<span class="Italics">Acute Rejection and Graft Loss with Corticosteroid Minimization</span>: corticosteroid utilization should be consistent with the NULOJIX clinical trial experience. <a href="#s2.1">(2.1</a>, <a href="#s5.7">5.7</a>, <a href="#s14.1">14.1)</a>
</dd>
<dt>•</dt>
<dd>
<span class="Italics">Immunizations</span>: avoid use of live vaccines during treatment. <a href="#s5.8">(5.8)</a>
</dd>
</dl></div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">Most common adverse reactions (≥20% on NULOJIX treatment) are <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infection</span>, <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">peripheral edema</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span>, graft dysfunction, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>, <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span>, and <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>. <a href="#s6.1">(6.1)</a> </p>
<p class="Highlighta"><span class="Bold"><br>To report SUSPECTED ADVERSE REACTIONS, contact Bristol-Myers Squibb at 1-800-721-5072 or FDA at 1-800-FDA-1088 or <span class="Italics"><span class="Underline">www.fda.gov/medwatch</span></span>.</span> </p>
</div>
<div>
<div><div></div></div>
<div></div>
<div></div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
</div>
<div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd>
<span class="Italics">Pregnancy</span>: Based on animal data, may cause fetal harm; pregnancy registry available. <a href="#s8.1">(8.1)</a>
</dd>
<dt>•</dt>
<dd>
<span class="Italics">Nursing Mothers</span>: Discontinue drug or nursing, taking into consideration importance of drug to mother. <a href="#s8.3">(8.3)</a>
</dd>
</dl></div>
<div><div></div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div><div>
<div></div>
<div></div>
</div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div><div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
</div></div>
<div><div></div></div>
<div><div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.</p>
<p class="HighlightsRevision">Revised: 9/2014</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">WARNING: POST-TRANSPLANT <span class="product-label-link" type="condition" conceptid="4079147" conceptname="Lymphoproliferative disorder">LYMPHOPROLIFERATIVE DISORDER</span>, OTHER MALIGNANCIES, AND SERIOUS <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">INFECTIONS</span></a></h1>
<h1><a href="#section-1" class="toc">1  INDICATIONS AND USAGE</a></h1>
<h2><a href="#section-1.1" class="toc">1.1  Adult Kidney Transplant Recipients</a></h2>
<h2><a href="#section-1.2" class="toc">1.2  Limitations of Use</a></h2>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Dosage in Adult Kidney Transplant Recipients</a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Preparation and Administration Instructions</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 Post-Transplant <span class="product-label-link" type="condition" conceptid="4079147" conceptname="Lymphoproliferative disorder">Lymphoproliferative Disorder</span></a></h2>
<h2><a href="#section-5.2" class="toc">5.2  Management of <span class="product-label-link" type="condition" conceptid="4242843" conceptname="Immunosuppression">Immunosuppression</span></a></h2>
<h2><a href="#section-5.3" class="toc">5.3  Other Malignancies</a></h2>
<h2><a href="#section-5.4" class="toc">5.4  <span class="product-label-link" type="condition" conceptid="433957" conceptname="Progressive multifocal leukoencephalopathy">Progressive Multifocal Leukoencephalopathy</span></a></h2>
<h2><a href="#section-5.5" class="toc">5.5  Other Serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></a></h2>
<h2><a href="#section-5.6" class="toc">5.6  Liver Transplant</a></h2>
<h2><a href="#section-5.7" class="toc">5.7  Acute Rejection and Graft Loss with Corticosteroid Minimization</a></h2>
<h2><a href="#section-5.8" class="toc">5.8  Immunizations</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1  Clinical Studies Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1  Mycophenolate Mofetil (MMF)</a></h2>
<h2><a href="#section-7.2" class="toc">7.2  Cytochrome P450 Substrates</a></h2>
<h1><a href="#section-8" class="toc">8  USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h2><a href="#section-11.3" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h2><a href="#section-12.2" class="toc">13.2 Animal Toxicology and/or Pharmacology</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h2><a href="#section-13.1" class="toc">14.1 Prevention of Organ Rejection in Kidney Transplant Recipients</a></h2>
<h1><a href="#section-14" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h2><a href="#section-14.1" class="toc">16.1 Storage</a></h2>
<h1><a href="#section-15" class="toc">17  PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="s0"></a><a name="section-1"></a><p></p>
<h1>WARNING: POST-TRANSPLANT <span class="product-label-link" type="condition" conceptid="4079147" conceptname="Lymphoproliferative disorder">LYMPHOPROLIFERATIVE DISORDER</span>, OTHER MALIGNANCIES, AND SERIOUS <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">INFECTIONS</span></h1>
<p class="First"><span class="Bold">Increased risk for developing post-transplant <span class="product-label-link" type="condition" conceptid="4079147" conceptname="Lymphoproliferative disorder">lymphoproliferative disorder</span> (PTLD), predominantly involving the central nervous system (CNS). Recipients without immunity to Epstein-Barr virus (EBV) are at a particularly increased risk; therefore, use in EBV seropositive patients only. Do not use NULOJIX in transplant recipients who are EBV seronegative or with unknown EBV serostatus [see <span class="Italics"><a href="#s4">Contraindications (4)</a></span> and <span class="Italics"><a href="#s5.1">Warnings and Precautions (5.1)</a></span>].</span></p>
<p><span class="Bold">Only physicians experienced in immunosuppressive therapy and management of kidney transplant patients should prescribe NULOJIX. Patients receiving the drug should be managed in facilities equipped and staffed with adequate laboratory and supportive medical resources. The physician responsible for maintenance therapy should have complete information requisite for the follow-up of the patient [see <span class="Italics"><a href="#s5.2">Warnings and Precautions (5.2)</a></span>].</span></p>
<p><span class="Bold">Increased susceptibility to <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> and the possible development of malignancies may result from <span class="product-label-link" type="condition" conceptid="4242843" conceptname="Immunosuppression">immunosuppression</span> [see <span class="Italics"><a href="#s5.1">Warnings and Precautions (5.1</a>, <a href="#s5.3">5.3</a>, <a href="#s5.4">5.4</a>, <a href="#s5.5">5.5)</a></span>].</span></p>
<p><span class="Bold">Use in liver transplant patients is not recommended due to an increased risk of graft loss and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> [see <span class="Italics"><a href="#s5.6">Warnings and Precautions (5.6)</a></span>].</span></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="s1"></a><a name="section-1"></a><p></p>
<h1>1  INDICATIONS AND USAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s1.1"></a><a name="section-1.1"></a><p></p>
<h2>1.1  Adult Kidney Transplant Recipients</h2>
<p class="First">NULOJIX<span class="Sup">®</span> (belatacept) is indicated for prophylaxis of organ rejection in adult patients receiving a kidney transplant. NULOJIX is to be used in combination with basiliximab induction, mycophenolate mofetil, and corticosteroids.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s1.2"></a><a name="section-1.2"></a><p></p>
<h2>1.2  Limitations of Use</h2>
<p class="First">Use NULOJIX only in patients who are EBV seropositive [see <span class="Italics"><a href="#s4">Contraindications (4)</a></span> and <span class="Italics"><a href="#s5.1">Warnings and Precautions (5.1)</a></span>].</p>
<p>Use of NULOJIX for the prophylaxis of organ rejection in transplanted organs other than kidney has not been established [see <span class="Italics"><a href="#s5.6">Warnings and Precautions (5.6)</a></span>].</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="s2"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s2.1"></a><a name="section-2.1"></a><p></p>
<h2>2.1 Dosage in Adult Kidney Transplant Recipients</h2>
<p class="First">NULOJIX should be administered in combination with basiliximab induction, mycophenolate mofetil (MMF), and corticosteroids. In clinical trials the median (25th-75th percentile) corticosteroid doses were tapered to approximately 15 mg (10-20 mg) per day by the first 6 weeks and remained at approximately 10 mg (5-10 mg) per day for the first 6 months post-transplant. Corticosteroid utilization should be consistent with the NULOJIX clinical trial experience [see <span class="Italics"><a href="#s5.7">Warnings and Precautions (5.7)</a></span> and <span class="Italics"><a href="#s14.1">Clinical Studies (14.1)</a></span>].</p>
<p>Due to an increased risk of post-transplant <span class="product-label-link" type="condition" conceptid="4079147" conceptname="Lymphoproliferative disorder">lymphoproliferative disorder</span> (PTLD) predominantly involving the central nervous system (CNS), <span class="product-label-link" type="condition" conceptid="433957" conceptname="Progressive multifocal leukoencephalopathy">progressive multifocal leukoencephalopathy</span> (PML), and serious CNS <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, administration of higher than the recommended doses or more frequent dosing of NULOJIX is not recommended [see <span class="Italics"><a href="#s5.1">Warnings and Precautions (5.1</a>, <a href="#s5.4">5.4</a>, <a href="#s5.5">5.5)</a></span> and <span class="Italics"><a href="#s6.1">Adverse Reactions (6.1)</a></span>].</p>
<p>NULOJIX is for intravenous infusion only. Patients do not require premedication prior to administration of NULOJIX.</p>
<p>Dosing instructions are provided in Table 1.</p>
<dl>
<dt>•</dt>
<dd>The total infusion dose of NULOJIX should be based on the actual body weight of the patient at the time of transplantation, and should not be modified during the course of therapy, unless there is a change in body weight of greater than 10%.</dd>
<dt>•</dt>
<dd>The prescribed dose of NULOJIX must be evenly divisible by 12.5 mg in order for the dose to be prepared accurately using the reconstituted solution and the <span class="Italics"><span class="Underline">silicone-free disposable syringe</span></span> provided. Evenly divisible increments are 0, 12.5, 25, 37.5, 50, 62.5, 75, 87.5, and 100. For example:<dl>
<dt>•</dt>
<dd><span class="Italics">A patient weighs 64 kg. The dose is 10 mg per kg.</span></dd>
<dt>•</dt>
<dd><span class="Italics">Calculated Dose: 64 kg × 10 mg per kg = 640 mg</span></dd>
<dt>•</dt>
<dd><span class="Italics">The closest doses evenly divisible by 12.5 mg below and above 640 mg are 637.5 mg and 650 mg.</span></dd>
<dt>•</dt>
<dd><span class="Italics">The nearest dose to 640 mg is 637.5 mg.</span></dd>
<dt>•</dt>
<dd><span class="Italics">Therefore, the actual prescribed dose for the patient should be 637.5 mg.</span></dd>
</dl>
</dd>
</dl>
<table cellpadding="2.4pt" width="100%">
<caption><span>Table 1: Dosing*<span class="Sup">,†</span> of NULOJIX for Kidney Transplant Recipients</span></caption>
<col width="70%">
<col width="30%">
<tfoot><tr class="First Last"><td class="Botrule" align="left" colspan="2" valign="top">* [See <span class="Emphasis"><span class="Italics"><a href="#s14.1">Clinical Studies (14.1)</a></span></span>.]<br><span class="Sup">†</span> The dose prescribed for the patient must be evenly divisible by 12.5 mg (see instructions above; e.g., evenly divisible increments are 0, 12.5, 25, 37.5, 50, 62.5, 75, 87.5, and 100).</td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Toprule"><p class="First"><span class="Bold">Dosing for Initial Phase</span></p></td>
<td class="Botrule Toprule" align="center"><p class="First"><span class="Bold">Dose</span></p></td>
</tr>
<tr>
<td class="Toprule"><p class="First">   Day 1 (day of transplantation, prior to implantation) and Day 5 (approximately 96 hours after Day 1 dose)</p></td>
<td class="Toprule" align="center"><p class="First">10 mg per kg</p></td>
</tr>
<tr>
<td><p class="First">   End of Week 2 and Week 4 after transplantation</p></td>
<td align="center"><p class="First">10 mg per kg</p></td>
</tr>
<tr>
<td class="Botrule"><p class="First">   End of Week 8 and Week 12 after transplantation</p></td>
<td class="Botrule" align="center"><p class="First">10 mg per kg</p></td>
</tr>
<tr>
<td class="Botrule"><p class="First"><span class="Bold">Dosing for Maintenance Phase</span></p></td>
<td class="Botrule" align="center"><p class="First"><span class="Bold">Dose</span></p></td>
</tr>
<tr class="Last">
<td class="Botrule"><p class="First">   End of Week 16 after transplantation and every 4 weeks (plus or minus 3 days) thereafter</p></td>
<td class="Botrule" align="center"><p class="First">5 mg per kg</p></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s2.2"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Preparation and Administration Instructions</h2>
<p class="First">NULOJIX is for intravenous infusion only.</p>
<p><span class="Bold">Caution:</span> NULOJIX must be reconstituted/prepared using only the <span class="Italics"><span class="Underline">silicone-free disposable syringe</span></span> provided with each vial.</p>
<p>If the <span class="Italics"><span class="Underline">silicone-free disposable syringe</span></span> is dropped or becomes contaminated, use a new <span class="Italics"><span class="Underline">silicone-free disposable syringe</span></span> from inventory. For information on obtaining additional <span class="Italics"><span class="Underline">silicone-free disposable syringes</span></span>, contact Bristol-Myers Squibb at 1-888-NULOJIX.</p>
<div class="Section" data-sectionCode="34068-7">
<a name="s2.2.1"></a><a name="section-2.2.1"></a><p></p>
<h3>Preparation for Administration</h3>
<dl>
<dt>1.</dt>
<dd>Calculate the number of NULOJIX vials required to provide the total infusion dose. Each vial contains 250 mg of belatacept lyophilized powder.</dd>
<dt>2.</dt>
<dd>Reconstitute the contents of each vial of NULOJIX with 10.5 mL of a suitable diluent using the <span class="Italics"><span class="Underline">silicone-free disposable syringe</span></span> provided with each vial and an 18- to 21-gauge needle. Suitable diluents include: sterile water for injection (SWFI), 0.9% sodium chloride (NS), or 5% dextrose in water (D5W).<br><span class="Italics">Note: If the NULOJIX powder is accidentally reconstituted using a different syringe than the one provided, the solution may develop a few translucent particles. Discard any solutions prepared using siliconized syringes.</span>
</dd>
<dt>3.</dt>
<dd>To reconstitute the NULOJIX powder, remove the flip-top from the vial and wipe the top with an alcohol swab. Insert the syringe needle into the vial through the center of the rubber stopper and direct the stream of diluent (10.5 mL of SWFI, NS, or D5W) to the glass wall of the vial.</dd>
<dt>4.</dt>
<dd>To minimize foam formation, rotate the vial and invert with gentle swirling until the contents are completely dissolved. Avoid prolonged or vigorous <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>. Do not shake.</dd>
<dt>5.</dt>
<dd>The reconstituted solution contains a belatacept concentration of 25 mg/mL and should be clear to slightly opalescent and colorless to <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> yellow. Do not use if opaque particles, discoloration, or other foreign particles are present.</dd>
<dt>6.</dt>
<dd>Calculate the total volume of the reconstituted 25 mg/mL NULOJIX solution required to provide the total infusion dose.<br>Volume of 25 mg/mL NULOJIX solution (in mL) = Prescribed Dose (in mg) ÷ 25 mg/mL</dd>
<dt>7.</dt>
<dd>Prior to intravenous infusion, the required volume of the reconstituted NULOJIX solution must be further diluted with a suitable infusion fluid (NS or D5W). NULOJIX reconstituted with:<dl>
<dt>•</dt>
<dd>SWFI should be further diluted with either NS or D5W</dd>
<dt>•</dt>
<dd>NS should be further diluted with NS</dd>
<dt>•</dt>
<dd>D5W should be further diluted with D5W</dd>
</dl>
</dd>
<dt>8.</dt>
<dd>From the appropriate size infusion bag or bottle, withdraw a volume of infusion fluid that is equal to the volume of the reconstituted NULOJIX solution required to provide the prescribed dose. With the same <span class="Italics"><span class="Underline">silicone-free disposable syringe</span></span> used for reconstitution, withdraw the required amount of belatacept solution from the vial, inject it into the infusion bag or bottle, and gently rotate the infusion bag or bottle to ensure mixing.<br>The final belatacept concentration in the infusion bag or bottle should range from 2 mg/mL to 10 mg/mL. Typically, an infusion volume of 100 mL will be appropriate for most patients and doses, but total infusion volumes ranging from 50 mL to 250 mL may be used. Any unused solution remaining in the vials must be discarded.</dd>
<dt>9.</dt>
<dd>Prior to administration, the NULOJIX infusion should be inspected visually for particulate matter and discoloration. Discard the infusion if any particulate matter or discoloration is observed.</dd>
<dt>10.</dt>
<dd>The entire NULOJIX infusion should be administered over a period of 30 minutes and must be administered with an infusion set and a sterile, non-pyrogenic, low-protein-binding filter (with a pore size of 0.2-1.2 µm).<dl>
<dt>•</dt>
<dd>The reconstituted solution should be transferred from the vial to the infusion bag or bottle immediately. The NULOJIX infusion must be completed within 24 hours of reconstitution of the NULOJIX lyophilized powder. If not used immediately, the infusion solution may be stored under refrigeration conditions: 2°-8°C (36°-46°F) and protected from light for up to 24 hours (a maximum of 4 hours of the total 24 hours can be at room temperature: 20°-25°C [68°-77°F] and room light).</dd>
<dt>•</dt>
<dd>Infuse NULOJIX in a separate line from other concomitantly infused agents. NULOJIX should not be infused concomitantly in the same intravenous line with other agents. No physical or biochemical compatibility studies have been conducted to evaluate the coadministration of NULOJIX with other agents.</dd>
</dl>
</dd>
</dl>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="s3"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">Lyophilized powder for injection: 250 mg per vial.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="s4"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">NULOJIX is contraindicated in transplant recipients who are Epstein-Barr virus (EBV) seronegative or with unknown EBV serostatus due to the risk of post-transplant <span class="product-label-link" type="condition" conceptid="4079147" conceptname="Lymphoproliferative disorder">lymphoproliferative disorder</span> (PTLD), predominantly involving the central nervous system (CNS) [see <span class="Italics"><a href="#s0">Boxed Warning</a></span> and <span class="Italics"><a href="#s5.1">Warnings and Precautions (5.1)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="s5"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s5.1"></a><a name="section-5.1"></a><p></p>
<h2>5.1 Post-Transplant <span class="product-label-link" type="condition" conceptid="4079147" conceptname="Lymphoproliferative disorder">Lymphoproliferative Disorder</span></h2>
<p class="First">NULOJIX-treated patients have an increased risk for developing post-transplant <span class="product-label-link" type="condition" conceptid="4079147" conceptname="Lymphoproliferative disorder">lymphoproliferative disorder</span> (PTLD), predominantly involving the CNS, compared to patients on a cyclosporine-based regimen [see <span class="Italics"><a href="#s6.1">Adverse Reactions (6.1)</a></span> and <span class="Italics">Table 2</span>]. As the total burden of <span class="product-label-link" type="condition" conceptid="4242843" conceptname="Immunosuppression">immunosuppression</span> is a risk factor for PTLD, higher than the recommended doses or more frequent dosing of NULOJIX and higher than recommended doses of concomitant immunosuppressive agents are not recommended [see <span class="Italics"><a href="#s2.1">Dosage and Administration (2.1)</a></span> and <span class="Italics"><a href="#s5.6">Warnings and Precautions (5.6)</a></span>]. Physicians should consider PTLD in patients reporting new or worsening neurological, cognitive, or behavioral signs or symptoms.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s5.1.1"></a><a name="section-5.1.1"></a><p></p>
<h3>EBV Serostatus</h3>
<p class="First">The risk of PTLD was higher in EBV seronegative patients compared to EBV seropositive patients. EBV seropositive patients are defined as having evidence of acquired immunity shown by the presence of IgG antibodies to viral capsid antigen (VCA) and EBV nuclear antigen (EBNA).</p>
<p>Epstein-Barr virus serology should be ascertained before starting administration of NULOJIX, and only patients who are EBV seropositive should receive NULOJIX. Transplant recipients who are EBV seronegative, or with unknown serostatus, should not receive NULOJIX [see <span class="Italics"><a href="#s0">Boxed Warning</a></span> and <span class="Italics"><a href="#s4">Contraindications (4)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s5.1.2"></a><a name="section-5.1.2"></a><p></p>
<h3>Other Risk Factors</h3>
<p class="First">Other known risk factors for PTLD include cytomegalovirus (CMV) <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> and T-cell-depleting therapy. T-cell-depleting therapies to treat acute rejection should be used cautiously. CMV prophylaxis is recommended for at least 3 months after transplantation [see <span class="Italics"><a href="#s5.5">Warnings and Precautions (5.5)</a></span>].</p>
<p>Patients who are EBV seropositive and CMV seronegative may be at increased risk for PTLD compared to patients who are EBV seropositive and CMV seropositive [see <span class="Italics"><a href="#s6.1">Adverse Reactions (6.1)</a></span>]. Since CMV seronegative patients are at increased risk for CMV disease (a known risk factor for PTLD), the clinical significance of CMV serology for PTLD remains to be determined; however, these findings should be considered when prescribing NULOJIX.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s5.2"></a><a name="section-5.2"></a><p></p>
<h2>5.2  Management of <span class="product-label-link" type="condition" conceptid="4242843" conceptname="Immunosuppression">Immunosuppression</span></h2>
<p class="First">Only physicians experienced in management of systemic immunosuppressant therapy in transplantation should prescribe NULOJIX. Patients receiving the drug should be managed in facilities equipped and staffed with adequate laboratory and supportive medical resources. The physician responsible for the maintenance therapy should have complete information requisite for the follow-up of the patient [see <span class="Italics"><a href="#s0">Boxed Warning</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s5.3"></a><a name="section-5.3"></a><p></p>
<h2>5.3  Other Malignancies</h2>
<p class="First">Patients receiving immunosuppressants, including NULOJIX, are at increased risk of developing malignancies, in addition to PTLD, including the skin [see <span class="Italics"><a href="#s0">Boxed Warning</a></span> and <span class="Italics"><a href="#s5.1">Warnings and Precautions (5.1)</a></span>]. Exposure to sunlight and ultraviolet (UV) light should be limited by wearing protective clothing and using a sunscreen with a high protection factor.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s5.4"></a><a name="section-5.4"></a><p></p>
<h2>5.4  <span class="product-label-link" type="condition" conceptid="433957" conceptname="Progressive multifocal leukoencephalopathy">Progressive Multifocal Leukoencephalopathy</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="433957" conceptname="Progressive multifocal leukoencephalopathy">Progressive multifocal leukoencephalopathy</span> (PML) is an often rapidly progressive and fatal <span class="product-label-link" type="condition" conceptid="4247535" conceptname="Opportunistic infectious disease">opportunistic infection</span> of the CNS that is caused by the JC virus, a human polyoma virus. In clinical trials with NULOJIX, two cases of PML were reported in patients receiving NULOJIX at higher cumulative doses and more frequently than the recommended regimen, along with mycophenolate mofetil (MMF) and corticosteroids; one case occurred in a kidney transplant recipient and the second case occurred in a liver transplant recipient [see <span class="Italics"><a href="#s5.6">Warnings and Precautions (5.6)</a></span>]. As PML has been associated with high levels of overall <span class="product-label-link" type="condition" conceptid="4242843" conceptname="Immunosuppression">immunosuppression</span>, the recommended doses and frequency of NULOJIX and concomitant immunosuppressives, including MMF, should not be exceeded.</p>
<p>Physicians should consider PML in the differential diagnosis in patients with new or worsening neurological, cognitive, or behavioral signs or symptoms. PML is usually diagnosed by brain imaging, cerebrospinal fluid (CSF) testing for JC viral DNA by <span class="product-label-link" type="condition" conceptid="4120014" conceptname="Polymerase chain reaction">polymerase chain reaction</span> (PCR), and/or brain biopsy. Consultation with a specialist (e.g., neurologist and/or infectious disease) should be considered for any suspected or confirmed cases of PML.</p>
<p>If PML is diagnosed, consideration should be given to reduction or withdrawal of <span class="product-label-link" type="condition" conceptid="4242843" conceptname="Immunosuppression">immunosuppression</span> taking into account the risk to the allograft.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s5.5"></a><a name="section-5.5"></a><p></p>
<h2>5.5  Other Serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></h2>
<p class="First">Patients receiving immunosuppressants, including NULOJIX, are at increased risk of developing bacterial, viral (cytomegalovirus [CMV] and herpes), fungal, and protozoal <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, including <span class="product-label-link" type="condition" conceptid="4247535" conceptname="Opportunistic infectious disease">opportunistic infections</span>. These <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> may lead to serious, including fatal, outcomes [see <span class="Italics"><a href="#s0">Boxed Warning</a></span> and <span class="Italics"><a href="#s6.1">Adverse Reactions (6.1)</a></span>].</p>
<p>Prophylaxis for cytomegalovirus is recommended for at least 3 months after transplantation. Prophylaxis for <span class="Italics">Pneumocystis jiroveci</span> is recommended after transplantation.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s5.5.1"></a><a name="section-5.5.1"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">Tuberculosis</span></h3>
<p class="First"><span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">Tuberculosis</span> was more frequently observed in patients receiving NULOJIX than cyclosporine in clinical trials [see <span class="Italics"><a href="#s6.1">Adverse Reactions (6.1)</a></span>]. Patients should be evaluated for <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> and tested for latent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> prior to initiating NULOJIX. Treatment of latent <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> should be initiated prior to NULOJIX use.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s5.5.2"></a><a name="section-5.5.2"></a><p></p>
<h3>Polyoma Virus <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">Nephropathy</span></h3>
<p class="First">In addition to cases of JC virus-associated PML [see <span class="Italics"><a href="#s5.4">Warnings and Precautions (5.4)</a></span>], cases of polyoma virus-associated <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">nephropathy</span> (PVAN), mostly due to BK virus <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, have been reported. PVAN is associated with serious outcomes; including deteriorating renal function and kidney graft loss [see <span class="Italics"><a href="#s6.1">Adverse Reactions (6.1)</a></span>]. Patient monitoring may help detect patients at risk for PVAN. Reductions in <span class="product-label-link" type="condition" conceptid="4242843" conceptname="Immunosuppression">immunosuppression</span> should be considered for patients who develop evidence of PVAN. Physicians should also consider the risk that reduced <span class="product-label-link" type="condition" conceptid="4242843" conceptname="Immunosuppression">immunosuppression</span> represents to the functioning allograft.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s5.6"></a><a name="section-5.6"></a><p></p>
<h2>5.6  Liver Transplant</h2>
<p class="First">Use of NULOJIX in liver transplant patients is not recommended [see <span class="Italics"><a href="#s0">Boxed Warning</a></span>]. In a clinical trial of liver transplant patients, use of NULOJIX regimens with more frequent administration of belatacept than any of those studied in kidney transplant, along with mycophenolate mofetil (MMF) and corticosteroids, was associated with a higher rate of graft loss and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> compared to the tacrolimus control arms. In addition, two cases of PTLD involving the liver allograft (one fatal) and one fatal case of PML were observed among the 147 patients randomized to NULOJIX. The two cases of PTLD were reported among the 140 EBV seropositive patients (1.4%). The fatal case of PML was reported in a patient receiving higher than recommended doses of NULOJIX and MMF [see <span class="Italics"><a href="#s5.4">Warnings and Precautions (5.4)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s5.7"></a><a name="section-5.7"></a><p></p>
<h2>5.7  Acute Rejection and Graft Loss with Corticosteroid Minimization</h2>
<p class="First">In postmarketing experience, use of NULOJIX in conjunction with basiliximab induction, MMF, and corticosteroid minimization to 5 mg per day between Day 3 and Week 6 post-transplant was associated with an increased rate and grade of acute rejection, particularly Grade III rejection. These Grade III rejections occurred in patients with 4 to 6 HLA mismatches. Graft loss was a consequence of Grade III rejection in some patients.</p>
<p>Corticosteroid utilization should be consistent with the NULOJIX clinical trial experience [see <span class="Italics"><a href="#s2.1">Dosage and Administration (2.1)</a></span> and <span class="Italics"><a href="#s14.1">Clinical Studies (14.1)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s5.8"></a><a name="section-5.8"></a><p></p>
<h2>5.8  Immunizations</h2>
<p class="First">The use of live vaccines should be avoided during treatment with NULOJIX, including but not limited to the following: intranasal <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">influenza</span>, <span class="product-label-link" type="condition" conceptid="4030555" conceptname="Measles">measles</span>, <span class="product-label-link" type="condition" conceptid="4290000" conceptname="Mumps">mumps</span>, <span class="product-label-link" type="condition" conceptid="4273323" conceptname="Rubella">rubella</span>, oral <span class="product-label-link" type="condition" conceptid="136330" conceptname="Acute nonparalytic poliomyelitis">polio</span>, BCG, <span class="product-label-link" type="condition" conceptid="441210" conceptname="Yellow fever">yellow fever</span>, <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">varicella</span>, and TY21a <span class="product-label-link" type="condition" conceptid="192819" conceptname="Typhoid fever">typhoid</span> vaccines.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="s6"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First">The most serious adverse reactions reported with NULOJIX are:</p>
<dl>
<dt>•</dt>
<dd>PTLD, predominantly CNS PTLD, and other malignancies [see <span class="Italics"><a href="#s0">Boxed Warning</a></span> and <span class="Italics"><a href="#s5.1">Warnings and Precautions (5.1</a>, <a href="#s5.3">5.3)</a></span>]</dd>
<dt>•</dt>
<dd>Serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, including JC virus-associated PML and polyoma virus <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">nephropathy</span> [see <span class="Italics"><a href="#s5.4">Warnings and Precautions (5.4</a>, <a href="#s5.5">5.5</a>, <a href="#s5.6">5.6)</a></span>]</dd>
</dl>
<div class="Section" data-sectionCode="42229-5">
<a name="s6.1"></a><a name="section-6.1"></a><p></p>
<h2>6.1  Clinical Studies Experience</h2>
<p class="First">The data described below primarily derive from two randomized, active-controlled three-year trials of NULOJIX in <span class="Italics">de novo</span> kidney transplant patients. In Study 1 and Study 2, NULOJIX was studied at the recommended dose and frequency [see <span class="Italics"><a href="#s2.1">Dosage and Administration (2.1)</a></span>] in a total of 401 patients compared to a cyclosporine control regimen in a total of 405 patients. These two trials also included a total of 403 patients treated with a NULOJIX regimen of higher cumulative dose and more frequent dosing than recommended [see <span class="Italics"><a href="#s14.1">Clinical Studies (14.1)</a></span>]. All patients also received basiliximab induction, mycophenolate mofetil, and corticosteroids. Patients were treated and followed for 3 years.</p>
<p>CNS PTLD, PML, and other CNS <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> were more frequently observed in association with a NULOJIX regimen of higher cumulative dose and more frequent dosing compared to the recommended regimen; therefore, administration of higher than the recommended doses and/or more frequent dosing of NULOJIX is not recommended [see <span class="Italics"><a href="#s2.1">Dosage and Administration (2.1)</a></span>].</p>
<p>The average age of patients in Studies 1 and 2 in the NULOJIX recommended dose and cyclosporine control regimens was 49 years, ranging from 18 to 79 years. Approximately 70% of patients were male; 67% were white, 11% were black, and 22% other races. About 25% of patients were from the United States and 75% from other countries.</p>
<p>Because clinical trials are conducted under widely varying conditions, the adverse reaction rates observed cannot be directly compared to rates in other trials and may not reflect the rates observed in clinical practice.</p>
<p>The most commonly reported adverse reactions occurring in ≥20% of patients treated with the recommended dose and frequency of NULOJIX were <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infection</span>, <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">peripheral edema</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span>, graft dysfunction, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>, <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span>, and <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>.</p>
<p>The proportion of patients who discontinued treatment due to adverse reactions was 13% for the recommended NULOJIX regimen and 19% for the cyclosporine control arm through three years of treatment. The most common adverse reactions leading to discontinuation in NULOJIX-treated patients were <span class="product-label-link" type="condition" conceptid="440032" conceptname="Cytomegalovirus infection">cytomegalovirus infection</span> (1.5%) and <span class="product-label-link" type="condition" conceptid="199991" conceptname="Disorder of transplanted kidney">complications of transplanted kidney</span> (1.5%).</p>
<p>Information on selected significant adverse reactions observed during clinical trials is summarized below.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s6.1.1"></a><a name="section-6.1.1"></a><p></p>
<h3>Post-Transplant <span class="product-label-link" type="condition" conceptid="4079147" conceptname="Lymphoproliferative disorder">Lymphoproliferative Disorder</span></h3>
<p class="First">Reported cases of post-transplant <span class="product-label-link" type="condition" conceptid="4079147" conceptname="Lymphoproliferative disorder">lymphoproliferative disorder</span> (PTLD) up to 36 months post transplant were obtained for NULOJIX by pooling both dosage regimens of NULOJIX in Studies 1 and 2 (804 patients) with data from a third study in kidney transplantation (Study 3, 145 patients) which evaluated two NULOJIX dosage regimens similar, but slightly different, from those of Studies 1 and 2 (see Table 2). The total number of NULOJIX patients from these three studies (949) was compared to the pooled cyclosporine control groups from all three studies (476 patients).</p>
<p>Among 401 patients in Studies 1 and 2 treated with the recommended regimen of NULOJIX and the 71 patients in Study 3 treated with a very similar (but non-identical) NULOJIX regimen, there were 5 cases of PTLD: 3 in EBV seropositive patients and 2 in EBV seronegative patients. Two of the 5 cases presented with CNS involvement.</p>
<p>Among the 477 patients in Studies 1, 2, and 3 treated with the NULOJIX regimen of higher cumulative dose and more frequent dosing than recommended, there were 8 cases of PTLD: 2 in EBV seropositive patients and 6 in EBV seronegative or serostatus unknown patients. Six of the 8 cases presented with CNS involvement. Therefore, administration of higher than the recommended doses or more frequent dosing of NULOJIX is not recommended. [See <span class="Italics"><a href="#s2.1">Dosage and Administration (2.1)</a></span> and <span class="Italics"><a href="#s5.1">Warnings and Precautions (5.1)</a></span>.]</p>
<p>One of the 476 patients treated with cyclosporine developed PTLD, without CNS involvement.</p>
<p>All cases of PTLD reported up to 36 months post transplant in NULOJIX- or cyclosporine-treated patients presented within 18 months of transplantation.</p>
<p>Overall, the rate of PTLD in 949 patients treated with any of the NULOJIX regimens was 9-fold higher in those who were EBV seronegative or EBV serostatus unknown (8/139) compared to those who were EBV seropositive (5/810 patients). Therefore NULOJIX is recommended for use only in patients who are EBV seropositive [see <span class="Italics"><a href="#s0">Boxed Warning</a></span> and <span class="Italics"><a href="#s4">Contraindications (4)</a></span>].</p>
<table cellpadding="4.8pt" width="97.06%">
<caption><span>Table 2: Summary of PTLD Reported in Studies 1, 2, and 3 Through Three Years of Treatment</span></caption>
<col width="15%">
<col width="10%">
<col width="9%">
<col width="10%">
<col width="10%">
<col width="8%">
<col width="10%">
<col width="10%">
<col width="8%">
<col width="10%">
<thead>
<tr class="First">
<th class="Botrule Lrule Rrule Toprule" align="left" valign="top"><span class="Bold"> </span></th>
<th class="Botrule Lrule Rrule Toprule" align="center" colspan="3" valign="top">
<span class="Bold">NULOJIX</span><br><span class="Bold">Non-Recommended</span><br><span class="Bold">Regimen*</span><br><span class="Bold">(N=477)</span>
</th>
<th class="Botrule Lrule Rrule Toprule" align="center" colspan="3" valign="top">
<span class="Bold">NULOJIX</span><br><span class="Bold">Recommended</span><br><span class="Bold">Regimen<span class="Sup">†</span></span><br><span class="Bold">(N=472)</span>
</th>
<th class="Botrule Lrule Rrule Toprule" align="center" colspan="3" valign="top">
<span class="Bold">Cyclosporine</span><br><br><br><span class="Bold">(N=476)</span>
</th>
</tr>
<tr class="Last">
<th class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold">Trial</span></th>
<th class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<span class="Bold">EBV</span><br><span class="Bold">Positive</span><br><span class="Bold">(n=406)</span>
</th>
<th class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<span class="Bold">EBV</span><br><span class="Bold">Negative</span><br><span class="Bold">(n=43)</span>
</th>
<th class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<span class="Bold">EBV</span><br><span class="Bold">Unknown</span><br><span class="Bold">(n=28)</span>
</th>
<th class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<span class="Bold">EBV</span><br><span class="Bold">Positive</span><br><span class="Bold">(n=404)</span>
</th>
<th class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<span class="Bold">EBV</span><br><span class="Bold">Negative</span><br><span class="Bold">(n=48)</span>
</th>
<th class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<span class="Bold">EBV</span><br><span class="Bold">Unknown</span><br><span class="Bold">(n=20)</span>
</th>
<th class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<span class="Bold">EBV</span><br><span class="Bold">Positive</span><br><span class="Bold">(n=399)</span>
</th>
<th class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<span class="Bold">EBV</span><br><span class="Bold">Negative</span><br><span class="Bold">(n=57)</span>
</th>
<th class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<span class="Bold">EBV</span><br><span class="Bold">Unknown</span><br><span class="Bold">(n=20)</span>
</th>
</tr>
</thead>
<tfoot><tr class="First Last"><td class="Botrule" align="left" colspan="10" valign="top">*  Regimen with higher cumulative dose and more frequent dosing than the recommended NULOJIX regimen.<br><span class="Sup">†</span>  In Studies 1 and 2 the NULOJIX regimen is identical to the recommended regimen, but is slightly different in Study 3.</td></tr></tfoot>
<tbody>
<tr class="First"><td class="Botrule Lrule Rrule" colspan="10"><p class="First"><span class="Bold">Study 1</span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">CNS PTLD</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">1</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">1</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"> </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Non-CNS<br>PTLD</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">1</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">2</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">1</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"> </p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="10"><p class="First"><span class="Bold">Study 2</span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">CNS PTLD</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">1</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">1</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">1</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">1</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"> </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Non-CNS<br>PTLD</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">1</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"> </p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="10"><p class="First"><span class="Bold">Study 3</span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">CNS PTLD</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">2</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"> </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Non-CNS<br>PTLD</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">1</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"> </p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="Bold">Total (%)</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">2 (0.5)</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">5 (11.6)</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">1 (3.6)</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">3 (0.7)</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">2 (4.1)</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">0</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">0</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">1 (1.8)</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">0</span></p></td>
</tr>
</tbody>
</table>
<div class="Section" data-sectionCode="42229-5">
<a name="s6.1.1.1"></a><a name="section-6.1.1.1"></a><p></p>
<h4>EBV Seropositive Subpopulation</h4>
<p class="First">Among the 806 EBV seropositive patients with known CMV serostatus treated with either NULOJIX regimen in Studies 1, 2, and 3, two percent (2%; 4/210) of CMV seronegative patients developed PTLD compared to 0.2% (1/596) of CMV seropositive patients. Among the 404 EBV seropositive recipients treated with the recommended dosage regimen of NULOJIX, three PTLD cases were detected among 99 CMV seronegative patients (3%) and there was no case detected among 303 CMV seropositive patients. The clinical significance of CMV serology as a risk factor for PTLD remains to be determined; however, these findings should be considered when prescribing NULOJIX [see <span class="Italics"><a href="#s5.1">Warnings and Precautions (5.1)</a></span>].</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s6.1.2"></a><a name="section-6.1.2"></a><p></p>
<h3>Other Malignancies</h3>
<p class="First">Malignancies, excluding non-<span class="product-label-link" type="condition" conceptid="4049499" conceptname="Malignant melanoma">melanoma skin</span> cancer and PTLD, were reported in Study 1 and Study 2 in 3.5% (14/401) of patients treated with the recommended NULOJIX regimen and 3.7% (15/405) of patients treated with the cyclosporine control regimen. Non-<span class="product-label-link" type="condition" conceptid="4049499" conceptname="Malignant melanoma">melanoma skin</span> cancer was reported in 1.5% (6/401) of patients treated with the recommended NULOJIX regimen and in 3.7% (15/405) of patients treated with cyclosporine [see <span class="Italics"><a href="#s5.3">Warnings and Precautions (5.3)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s6.1.3"></a><a name="section-6.1.3"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="433957" conceptname="Progressive multifocal leukoencephalopathy">Progressive Multifocal Leukoencephalopathy</span></h3>
<p class="First">Two fatal cases of <span class="product-label-link" type="condition" conceptid="433957" conceptname="Progressive multifocal leukoencephalopathy">progressive multifocal leukoencephalopathy</span> (PML) have been reported among 1096 patients treated with a NULOJIX-containing regimen:  one patient in clinical trials of kidney transplant (Studies 1, 2, and 3 described above) and one patient in a trial of liver transplant (trial of 250 patients). No cases of PML were reported in patients treated with the recommended NULOJIX regimen or the control regimen in these trials.</p>
<p>The kidney transplant recipient was treated with the NULOJIX regimen of higher cumulative dose and more frequent dosing than recommended, mycophenolate mofetil (MMF), and corticosteroids for 2 years. The liver transplant recipient was treated with 6 months of a NULOJIX dosage regimen that was more intensive than that studied in kidney transplant recipients, MMF at doses higher than the recommended dose, and corticosteroids [see <span class="Italics"><a href="#s5.4">Warnings and Precautions (5.4)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s6.1.4"></a><a name="section-6.1.4"></a><p></p>
<h3>Bacterial, Mycobacterial, Viral, and <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">Fungal Infections</span></h3>
<p class="First">Adverse reactions of infectious etiology were reported based on clinical assessment by physicians. The causative organisms for these reactions are identified when provided by the physician. The overall number of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, and select <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> with identified etiology reported in patients treated with the NULOJIX recommended regimen or the cyclosporine control in Studies 1 and 2 are shown in Table 3. <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">Fungal infections</span> were reported in 18% of patients receiving NULOJIX compared to 22% receiving cyclosporine, primarily due to skin and mucocutaneous <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infections</span>. <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">Tuberculosis</span> and <span class="product-label-link" type="condition" conceptid="435463" conceptname="Herpesvirus infection">herpes infections</span> were reported more frequently in patients receiving NULOJIX than cyclosporine. Of the patients who developed <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> through 3 years, all but one NULOJIX patient lived in countries with a high prevalence of <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> [see <span class="Italics"><a href="#s5.5">Warnings and Precautions (5.5)</a></span>].</p>
<table cellpadding="4.8pt" width="100%">
<caption><span>Table 3: Overall <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> and Select <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> with Identified Etiology by Treatment Group following One and Three Years of Treatment in Studies 1 and 2*</span></caption>
<col width="28%">
<col width="18%">
<col width="18%">
<col width="18%">
<col width="18%">
<thead>
<tr class="First">
<th class="Lrule Rrule Toprule" align="left" valign="top"><span class="Bold"> </span></th>
<th class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="top"><span class="Bold">Up to Year 1</span></th>
<th class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="top"><span class="Bold">Up to Year 3<span class="Sup">†</span></span></th>
</tr>
<tr class="Last">
<th class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold"> </span></th>
<th class="Botrule Lrule Rrule" align="center" valign="top">
<span class="Bold">NULOJIX</span><br><span class="Bold">Recommended</span><br><span class="Bold">Regimen</span><br><span class="Bold">N=401</span><br><span class="Bold">n (%)</span>
</th>
<th class="Botrule Lrule Rrule" align="center" valign="top">
<span class="Bold">Cyclosporine</span><br><br><br><span class="Bold">N=405</span><br><span class="Bold">n (%)</span>
</th>
<th class="Botrule Lrule Rrule" align="center" valign="top">
<span class="Bold">NULOJIX</span><br><span class="Bold">Recommended</span><br><span class="Bold">Regimen</span><br><span class="Bold">N=401</span><br><span class="Bold">n (%)</span>
</th>
<th class="Botrule Lrule Rrule" align="center" valign="top">
<span class="Bold">Cyclosporine</span><br><br><br><span class="Bold">N=405</span><br><span class="Bold">n (%)</span>
</th>
</tr>
</thead>
<tfoot><tr class="First Last"><td class="Botrule" align="left" colspan="5" valign="top">*  Studies 1 and 2 were not designed to support comparative claims for NULOJIX for the adverse reactions reported in this table.<br><span class="Sup">†</span>  Median exposure in days for pooled studies: 1203 for NULOJIX recommended regimen and 1163 for cyclosporine in Studies 1 and 2.<br><span class="Sup">‡</span>  All <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> include bacterial, viral, fungal, and other organisms. For infectious adverse reactions, the causative organism is reported if specified by the physician in the clinical trials.<br><span class="Sup">§</span>  A medically important event that may be life-threatening or result in <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> or hospitalization or prolongation of existing hospitalization. <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> not meeting these criteria are considered non-serious.<br><span class="Sup">¶</span>  BK virus-associated <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">nephropathy</span> was reported in 6 NULOJIX patients (4 of which resulted in graft loss) and 6 cyclosporine patients (none of which resulted in graft loss) by Year 3.<br><span class="Sup">#</span>  Most <span class="product-label-link" type="condition" conceptid="435463" conceptname="Herpesvirus infection">herpes infections</span> were non-serious and 1 led to treatment discontinuation.</td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule Toprule"><p class="First">All <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span><span class="Sup">‡</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">287 (72)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">299 (74)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">329 (82)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">327 (81)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">   Serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span><span class="Sup">§</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">98 (24)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">113 (28)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">144 (36)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">157 (39)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">CMV</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">44 (11)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">52 (13)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">53 (13)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">56 (14)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Polyoma virus<span class="Sup">¶</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">10 (3)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">23 (6)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">17 (4)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">27 (7)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Herpes<span class="Sup">#</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">27 (7)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">26 (6)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">55 (14)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">46 (11)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">Tuberculosis</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">2 (1)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">1 (&lt;1)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">6 (2)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">1 (&lt;1)</p></td>
</tr>
</tbody>
</table>
<div class="Section" data-sectionCode="42229-5">
<a name="s6.1.4.1"></a><a name="section-6.1.4.1"></a><p></p>
<h4><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> Reported in the CNS</h4>
<p class="First">Following three years of treatment in Studies 1 and 2, <span class="product-label-link" type="condition" conceptid="432310" conceptname="Cryptococcal meningitis">cryptococcal meningitis</span> was reported in one patient out of 401 patients treated with the NULOJIX recommended regimen (0.2%) and one patient out of the 405 treated with the cyclosporine control (0.2%).</p>
<p>Six patients out of the 403 who were treated with the NULOJIX regimen of higher cumulative dose and more frequent dosing than recommended in Studies 1 and 2 (1.5%) were reported to have developed CNS <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, including 2 cases of <span class="product-label-link" type="condition" conceptid="432310" conceptname="Cryptococcal meningitis">cryptococcal meningitis</span>, one case of Chagas <span class="product-label-link" type="condition" conceptid="378143" conceptname="Encephalitis">encephalitis</span> with <span class="product-label-link" type="condition" conceptid="432310" conceptname="Cryptococcal meningitis">cryptococcal meningitis</span>, one case of cerebral <span class="product-label-link" type="condition" conceptid="434281" conceptname="Aspergillosis">aspergillosis</span>, one case of West Nile <span class="product-label-link" type="condition" conceptid="378143" conceptname="Encephalitis">encephalitis</span>, and one case of PML (discussed above).</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s6.1.5"></a><a name="section-6.1.5"></a><p></p>
<h3>Infusion Reactions</h3>
<p class="First">There were no reports of <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> or <span class="product-label-link" type="condition" conceptid="439224" conceptname="Drug allergy">drug hypersensitivity</span> in patients treated with NULOJIX in Studies 1 and 2 through three years.</p>
<p>Infusion-related reactions within one hour of infusion were reported in 5% of patients treated with the recommended dose of NULOJIX, similar to the placebo rate. No serious events were reported through Year 3. The most frequent reactions were <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> and <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s6.1.6"></a><a name="section-6.1.6"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">Proteinuria</span></h3>
<p class="First">At Month 1 after transplantation in Studies 1 and 2, the frequency of 2+ <span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">proteinuria</span> on urine dipstick in patients treated with the NULOJIX recommended regimen was 33% (130/390) and 28% (107/384) in patients treated with the cyclosporine control regimen. The frequency of 2+ <span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">proteinuria</span> was similar between the two treatment groups between one and three years after transplantation (&lt;10% in both studies). There were no differences in the occurrence of 3+ <span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">proteinuria</span> (&lt;4% in both studies) at any time point, and no patients experienced 4+ <span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">proteinuria</span>. The clinical significance of this increase in early <span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">proteinuria</span> is unknown.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s6.1.7"></a><a name="section-6.1.7"></a><p></p>
<h3>Immunogenicity</h3>
<p class="First">Antibodies directed against the belatacept molecule were assessed in 398 patients treated with the NULOJIX recommended regimen in Studies 1 and 2 (212 of these patients were treated for at least 2 years). Of the 372 patients with immunogenicity assessment at baseline (prior to receiving belatacept treatment), 29 patients tested positive for anti-belatacept antibodies; 13 of these patients had antibodies to the modified cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4). Anti-belatacept antibody titers did not increase during treatment in these 29 patients.</p>
<p>Eight (2%) patients developed antibodies during treatment with the NULOJIX recommended regimen. In the patients who developed antibodies during treatment, the median titer (by dilution method) was 8, with a range of 5 to 80. Of 56 patients who tested negative for antibodies during treatment and reassessed approximately 7 half-lives after discontinuation of NULOJIX, 1 tested antibody positive. Anti-belatacept antibody development was not associated with altered clearance of belatacept.</p>
<p>Samples from 6 patients with confirmed binding activity to the modified cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) region of the belatacept molecule were assessed by an <span class="Italics">in vitro</span> bioassay for the presence of neutralizing antibodies. Three of these 6 patients tested positive for neutralizing antibodies. However, the development of neutralizing antibodies may be underreported due to lack of assay sensitivity.</p>
<p>The clinical impact of anti-belatacept antibodies (including neutralizing anti-belatacept antibodies) could not be determined in the studies.</p>
<p>The data reflect the percentage of patients whose test results were positive for antibodies to belatacept in specific assays. The observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors including assay sensitivity and specificity, assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies to belatacept with the incidence of antibodies to other products may be misleading.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s6.1.8"></a><a name="section-6.1.8"></a><p></p>
<h3>New-Onset <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> After Transplantation</h3>
<p class="First"> The incidence of new-onset <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> after transplantation (NODAT) was defined in Studies 1 and 2 as use of an antidiabetic agent for ≥30 days or ≥2 fasting plasma glucose values ≥126 mg/dL (7.0 mmol/L) post-transplantation. Of the patients treated with the NULOJIX recommended regimen, 5% (14/304) developed NODAT by the end of one year compared to 10% (27/280) of patients on the cyclosporine control regimen. However, by the end of the third year, the cumulative incidence of NODAT was 8% (24/304) in patients treated with the NULOJIX recommended regimen and 10% (29/280) in patients treated with the cyclosporine regimen.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s6.1.9"></a><a name="section-6.1.9"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></h3>
<p class="First">Blood pressure and use of antihypertensive medications were reported in Studies 1 and 2. By Year 3, one or more antihypertensive medications were used in 85% of NULOJIX-treated patients and 92% of cyclosporine-treated patients. At one year after transplantation, systolic blood pressures were 8 mmHg lower and diastolic blood pressures were 3 mmHg lower in patients treated with the NULOJIX recommended regimen compared to the cyclosporine control regimen. At three years after transplantation, systolic blood pressures were 6 mmHg lower and diastolic blood pressures were 3 mmHg lower in NULOJIX-treated patients compared to cyclosporine-treated patients. <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span> was reported as an adverse reaction in 32% of NULOJIX-treated patients and 37% of cyclosporine-treated patients (see Table 4).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s6.1.10"></a><a name="section-6.1.10"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="4159131" conceptname="Dyslipidemia">Dyslipidemia</span></h3>
<p class="First">Mean values of total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>, HDL, LDL, and triglycerides were reported in Studies 1 and 2. At one year after transplantation these values were 183 mg/dL, 50 mg/dL, 102 mg/dL, and 151 mg/dL, respectively, in 401 patients treated with the NULOJIX recommended regimen and 196 mg/dL, 48 mg/dL, 108 mg/dL, and 195 mg/dL, respectively, in 405 patients treated with the cyclosporine control regimen. At three years after transplantation, the total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>, HDL, LDL, and triglycerides were 176 mg/dL, 49 mg/dL, 100 mg/dL, and 141 mg/dL, respectively, in NULOJIX-treated patients compared to 193 mg/dL, 48 mg/dL, 106 mg/dL, and 180 mg/dL in cyclosporine-treated patients.</p>
<p>The clinical significance of the lower mean triglyceride values in NULOJIX-treated patients at one and three years is unknown.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s6.1.11"></a><a name="section-6.1.11"></a><p></p>
<h3>Other Adverse Reactions</h3>
<p class="First">Adverse reactions that occurred at a frequency of ≥10% in patients treated with the NULOJIX recommended regimen or cyclosporine control regimen in Studies 1 and 2 through three years are summarized by preferred term in decreasing order of frequency within Table 4.</p>
<table cellpadding="4.8pt" width="100%">
<caption><span>Table 4: Adverse Reactions Reported by ≥10% of Patients Treated with Either the NULOJIX Recommended Regimen or Control in Studies 1 and 2 Through Three Years*<span class="Sup">,†</span></span></caption>
<col width="46%">
<col width="27%">
<col width="27%">
<thead><tr class="First Last">
<th class="Botrule Lrule Rrule Toprule" align="left" valign="top"><span class="Bold">Adverse Reaction</span></th>
<th class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<span class="Bold">NULOJIX</span><br><span class="Bold">Recommended Regimen</span><br><span class="Bold">N=401</span><br><span class="Bold">%</span>
</th>
<th class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<span class="Bold">Cyclosporine</span><br><br><span class="Bold">N=405</span><br><span class="Bold">%</span>
</th>
</tr></thead>
<tfoot><tr class="First Last"><td class="Botrule" align="left" colspan="3" valign="top">* All randomized and transplanted patients in Studies 1 and 2.<br><span class="Sup">†</span> Studies 1 and 2 were not designed to support comparative claims for NULOJIX for the adverse reactions reported in this table.</td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="Italics"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> and <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">Infestations</span></span></p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First"> </p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First"> </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">    <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary tract infection</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">37</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">36</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">    <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">Upper respiratory infection</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">15</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">16</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">    <span class="product-label-link" type="condition" conceptid="4197268" conceptname="Nasopharyngitis">Nasopharyngitis</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">13</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">16</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">    <span class="product-label-link" type="condition" conceptid="440032" conceptname="Cytomegalovirus infection">Cytomegalovirus infection</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">12</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">12</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">    <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">Influenza</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">11</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">8</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">    <span class="product-label-link" type="condition" conceptid="256451" conceptname="Bronchitis">Bronchitis</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">10</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">7</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span></span></p></td>
<td class="Botrule Lrule Rrule"><p class="First"> </p></td>
<td class="Botrule Lrule Rrule"><p class="First"> </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">    <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">39</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">36</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">    <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">33</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">35</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">    <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">24</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">27</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">    <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">22</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">20</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">    <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">19</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">16</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">    <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">Abdominal pain upper</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">9</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">10</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Italics">Metabolism and Nutrition Disorders</span></p></td>
<td class="Botrule Lrule Rrule"><p class="First"> </p></td>
<td class="Botrule Lrule Rrule"><p class="First"> </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">    <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">Hyperkalemia</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">20</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">20</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">    <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">21</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">14</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">    <span class="product-label-link" type="condition" conceptid="4177973" conceptname="Hypophosphatemia">Hypophosphatemia</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">19</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">13</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">    <span class="product-label-link" type="condition" conceptid="4159131" conceptname="Dyslipidemia">Dyslipidemia</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">19</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">24</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">    <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">Hyperglycemia</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">16</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">17</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">    <span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">Hypocalcemia</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">13</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">11</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">    <span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">Hypercholesterolemia</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">11</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">11</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">    <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">Hypomagnesemia</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">7</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">10</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">    <span class="product-label-link" type="condition" conceptid="4147761" conceptname="Hyperuricemia">Hyperuricemia</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">5</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">12</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Italics">Procedural Complications</span></p></td>
<td class="Botrule Lrule Rrule"><p class="First"> </p></td>
<td class="Botrule Lrule Rrule"><p class="First"> </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">    Graft dysfunction</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">25</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">34</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Italics">General Disorders</span></p></td>
<td class="Botrule Lrule Rrule"><p class="First"> </p></td>
<td class="Botrule Lrule Rrule"><p class="First"> </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">    <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">Peripheral edema</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">34</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">42</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">    <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Pyrexia</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">28</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">26</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Italics">Blood and Lymphatic System Disorders</span></p></td>
<td class="Botrule Lrule Rrule"><p class="First"> </p></td>
<td class="Botrule Lrule Rrule"><p class="First"> </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">    <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">45</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">44</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">    <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">Leukopenia</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">20</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">23</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Italics">Renal and Urinary Disorders</span></p></td>
<td class="Botrule Lrule Rrule"><p class="First"> </p></td>
<td class="Botrule Lrule Rrule"><p class="First"> </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">    <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">Hematuria</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">16</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">18</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">    <span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">Proteinuria</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">16</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">12</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">    <span class="product-label-link" type="condition" conceptid="197684" conceptname="Dysuria">Dysuria</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">11</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">11</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">    <span class="product-label-link" type="condition" conceptid="444044" conceptname="Acute tubular necrosis">Renal tubular necrosis</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">9</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">13</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Italics"><span class="product-label-link" type="condition" conceptid="443784" conceptname="Vascular disorder">Vascular Disorders</span></span></p></td>
<td class="Botrule Lrule Rrule"><p class="First"> </p></td>
<td class="Botrule Lrule Rrule"><p class="First"> </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">    <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">32</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">37</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">    <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">18</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">12</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Italics">Respiratory, Thoracic, and <span class="product-label-link" type="condition" conceptid="440142" conceptname="Disorder of mediastinum">Mediastinal Disorders</span></span></p></td>
<td class="Botrule Lrule Rrule"><p class="First"> </p></td>
<td class="Botrule Lrule Rrule"><p class="First"> </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">    <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">24</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">18</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">    <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">12</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">15</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Italics">Investigations</span></p></td>
<td class="Botrule Lrule Rrule"><p class="First"> </p></td>
<td class="Botrule Lrule Rrule"><p class="First"> </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">    Blood creatinine increased</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">15</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">20</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Italics">Musculoskeletal and <span class="product-label-link" type="condition" conceptid="253549" conceptname="Disorder of connective tissue">Connective Tissue Disorders</span></span></p></td>
<td class="Botrule Lrule Rrule"><p class="First"> </p></td>
<td class="Botrule Lrule Rrule"><p class="First"> </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">    <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">17</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">13</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">    <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back pain</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">13</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">13</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Italics"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span></span></p></td>
<td class="Botrule Lrule Rrule"><p class="First"> </p></td>
<td class="Botrule Lrule Rrule"><p class="First"> </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">    <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">21</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">18</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">    <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">9</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">10</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">    <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">Tremor</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">8</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">17</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Italics">Skin and Subcutaneous Tissue Disorders</span></p></td>
<td class="Botrule Lrule Rrule"><p class="First"> </p></td>
<td class="Botrule Lrule Rrule"><p class="First"> </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">    <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">Acne</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">8</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">11</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Italics">Psychiatric Disorders</span></p></td>
<td class="Botrule Lrule Rrule"><p class="First"> </p></td>
<td class="Botrule Lrule Rrule"><p class="First"> </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">    <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">15</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">18</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule"><p class="First">    <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">Anxiety</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">10</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">11</p></td>
</tr>
</tbody>
</table>
<p>Selected adverse reactions occurring in &lt;10% from NULOJIX-treated patients in either regimen through three years in Studies 1 and 2 are listed below:</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="440371" conceptname="Disorder of immune function">Immune System Disorders</span>:</span> Guillain-Barré syndrome</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> and <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">Infestations</span>:</span> see Table 3</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">stomatitis</span>, including <span class="product-label-link" type="condition" conceptid="138463" conceptname="Aphthous ulcer of mouth">aphthous stomatitis</span></p>
<p><span class="Bold">Injury, <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">Poisoning</span>, and Procedural Complications:</span> <span class="product-label-link" type="condition" conceptid="4032423" conceptname="Transplant glomerulopathy">chronic allograft nephropathy</span>, <span class="product-label-link" type="condition" conceptid="199991" conceptname="Disorder of transplanted kidney">complications of transplanted kidney</span>, including <span class="product-label-link" type="condition" conceptid="439981" conceptname="Wound dehiscence">wound dehiscence</span>, <span class="product-label-link" type="condition" conceptid="4125011" conceptname="Arteriovenous fistula thrombosis">arteriovenous fistula thrombosis</span></p>
<p><span class="Bold">Blood and Lymphatic System Disorders:</span> <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span></p>
<p><span class="Bold">Renal and Urinary Disorders:</span> <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, including <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span>, <span class="product-label-link" type="condition" conceptid="4118795" conceptname="Renal artery stenosis">renal artery stenosis</span>, <span class="product-label-link" type="condition" conceptid="197672" conceptname="Urinary incontinence">urinary incontinence</span>, <span class="product-label-link" type="condition" conceptid="433811" conceptname="Hydronephrosis">hydronephrosis</span></p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="443784" conceptname="Vascular disorder">Vascular Disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="4147001" conceptname="Hematoma">hematoma</span>, <span class="product-label-link" type="condition" conceptid="4119772" conceptname="Lymphocele">lymphocele</span></p>
<p><span class="Bold">Musculoskeletal and <span class="product-label-link" type="condition" conceptid="253549" conceptname="Disorder of connective tissue">Connective Tissue Disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="4150129" conceptname="Musculoskeletal pain">musculoskeletal pain</span></p>
<p><span class="Bold">Skin and Subcutaneous Tissue Disorders:</span> <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">hyperhidrosis</span></p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="321588" conceptname="Heart disease">Cardiac Disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span></p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="s7"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s7.1"></a><a name="section-7.1"></a><p></p>
<h2>7.1  Mycophenolate Mofetil (MMF)</h2>
<p class="First">Monitor for a need to adjust concomitant mycophenolate mofetil (MMF) dosage when patient’s therapy is switched between cyclosporine and NULOJIX, as cyclosporine decreases mycophenolic acid (MPA) exposure by preventing enterohepatic recirculation of MPA while NULOJIX does not [see <span class="Italics"><a href="#s12.3">Clinical Pharmacology (12.3)</a></span>]:</p>
<dl>
<dt>•</dt>
<dd>A higher MMF dosage may be needed after switching from NULOJIX to cyclosporine, since this may result in lower MPA concentrations and increase the risk of <span class="product-label-link" type="condition" conceptid="4248020" conceptname="Graft rejection">graft rejection</span>.</dd>
<dt>•</dt>
<dd>A lower MMF dosage may be needed after switching from cyclosporine to NULOJIX, since this may result in higher MPA concentrations and increase the risk for adverse reactions related to MPA (review the Full Prescribing Information for MMF).</dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s7.2"></a><a name="section-7.2"></a><p></p>
<h2>7.2  Cytochrome P450 Substrates</h2>
<p class="First">No dosage adjustments are needed for drugs metabolized via CYP1A2, CYP2C9, CYP2D6, CYP3A, and CYP2C19 when coadministered with NULOJIX [see <span class="Italics"><a href="#s12.3">Clinical Pharmacology (12.3)</a></span>].</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="s8"></a><a name="section-8"></a><p></p>
<h1>8  USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="s8.1"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="s8.1.1"></a><a name="section-8.1.1"></a><p></p>
<h3>Pregnancy Category C</h3>
<p class="First">NULOJIX should not be used in pregnancy unless the potential benefit to the mother outweighs the potential risk to the fetus. There are no studies of NULOJIX treatment in pregnant women. Belatacept is known to cross the placenta of animals. Belatacept was not teratogenic in pregnant rats and rabbits at doses approximately 16 and 19 times greater than the exposure associated with the maximum recommended human dose (MRHD) of 10 mg per kg administered over the first month of treatment, based on area under the concentration-time curve (AUC).</p>
<p>Belatacept administered to female rats daily during gestation and throughout the lactation period was associated with maternal toxicity (<span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>) in a small percentage of dams at doses of ≥20 mg per kg (≥3 times the MRHD exposure based on AUC) resulting in increased pup mortality (up to 100% pup mortality in some dams). In pups that survived, there were no abnormalities or malformations at doses up to 200 mg per kg (19 times the MRHD exposure).</p>
<p><span class="Italics">In vitro</span> data indicate that belatacept has lower binding affinity to CD80/CD86 and lower potency in rodents than in humans. Although the rat toxicity studies with belatacept were done at pharmacologically saturating doses, the <span class="Italics">in vivo</span> difference in potency between rats and humans is unknown. Therefore, the relevance of the rat toxicities to humans and the significance of the magnitude of the relative exposures (rats: humans) are unknown.</p>
<p>Abatacept, a fusion protein that differs from belatacept by 2 amino acids, binds to the same ligands (CD80/CD86) and blocks T-cell costimulation like belatacept, but is more active than belatacept in rodents. Therefore, toxicities identified with abatacept in rodents, including <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> and autoimmunity, may be predictive of adverse effects in humans treated with belatacept [see <span class="Italics"><a href="#s13.2">Nonclinical Toxicology (13.2)</a></span>].</p>
<p>Autoimmunity was observed in one rat offspring exposed to abatacept <span class="Italics">in utero</span> and/or during lactation and in juvenile rats after treatment with abatacept. However, the clinical relevance of autoimmunity in rats to patients or a fetus exposed <span class="Italics">in utero</span> is unknown [see <span class="Italics"><a href="#s13.2">Nonclinical Toxicology (13.2)</a></span>].</p>
<p><span class="Italics">Pregnancy Registry:</span> To monitor maternal-fetal outcomes of pregnant women who have received NULOJIX or whose partners have received NULOJIX, healthcare providers are strongly encouraged to register pregnant patients in the National Transplant Pregnancy Registry (NTPR) by calling 1-877-955-6877.</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="s8.3"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">It is not known whether belatacept is excreted in human milk or absorbed systemically after ingestion by a nursing infant. However, belatacept is excreted in rat milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions from NULOJIX in nursing infants, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="s8.4"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">The safety and efficacy of NULOJIX in patients under 18 years of age have not been established. Because T cell development continues into the teenage years, the potential concern for autoimmunity in neonates applies to pediatric use as well [see <span class="Italics"><a href="#s8.1">Use in Specific Populations (8.1)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="s8.5"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">Of 401 patients treated with the recommended dosage regimen of NULOJIX, 15% were 65 years of age and older, while 3% were 75 and older. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, but greater sensitivity or less efficacy in older individuals cannot be ruled out.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="s10"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">Single doses up to 20 mg per kg of NULOJIX have been administered to healthy subjects without apparent toxic effect. The administration of NULOJIX of higher cumulative dose and more frequent dosing than recommended in kidney transplant patients resulted in a higher frequency of CNS-related adverse reactions [see <span class="Italics"><a href="#s6.1">Adverse Reactions (6.1)</a></span>]. In case of overdosage, it is recommended that the patient be monitored for any signs or symptoms of adverse reactions and appropriate symptomatic treatment instituted.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="s11"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">NULOJIX<span class="Sup">®</span> (belatacept), a selective T-cell costimulation blocker, is a soluble fusion protein consisting of the modified extracellular domain of CTLA-4 fused to a portion (hinge-CH2-CH3 domains) of the Fc domain of a human immunoglobulin G1 antibody. Belatacept is produced by recombinant DNA technology in a mammalian cell expression system. Two amino acid substitutions (L104 to E; A29 to Y) were made in the ligand binding region of CTLA-4. As a result of these modifications, belatacept binds CD80 and CD86 more avidly than abatacept, the parent CTLA4-Immunoglobulin (CTLA4-Ig) molecule from which it is derived. The molecular weight of belatacept is approximately 90 kilodaltons.</p>
<p>NULOJIX is supplied as a sterile, white or off-white lyophilized powder for intravenous administration. Prior to use, the lyophile is reconstituted with a suitable fluid to obtain a clear to slightly opalescent, colorless to <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> yellow solution, with a pH in the range of 7.2 to 7.8. Suitable fluids for constitution of the lyophile include SWFI, 0.9% NS, or D5W [see <span class="Italics"><a href="#s2.2">Dosage and Administration (2.2)</a></span>]. Each 250 mg single-use vial of NULOJIX also contains: monobasic sodium phosphate (34.5 mg), sodium chloride (5.8 mg), and sucrose (500 mg).</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="s12"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="s12.1"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">Belatacept, a selective T-cell (lymphocyte) costimulation blocker, binds to CD80 and CD86 on antigen-presenting cells thereby blocking CD28 mediated costimulation of T <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span>. <span class="Italics">In vitro</span>, belatacept inhibits T lymphocyte proliferation and the production of the cytokines interleukin-2, interferon-γ, interleukin-4, and TNF-α. Activated T <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span> are the predominant mediators of immunologic rejection.</p>
<p>In non-human primate models of renal transplantation, belatacept monotherapy prolonged graft survival and decreased the production of anti-donor antibodies, compared to vehicle.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="s12.2"></a><a name="section-11.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<p class="First">Belatacept-mediated costimulation blockade results in the inhibition of cytokine production by T cells required for antigen-specific antibody production by B cells. In clinical trials, greater reductions in mean immunoglobulin (IgG, IgM, and IgA) concentrations were observed from baseline to Month 6 and Month 12 post-transplant in belatacept-treated patients compared to cyclosporine-treated patients. In an exploratory subset analysis, a trend of decreasing IgG concentrations with increasing belatacept trough concentrations was observed at Month 6. Also in this exploratory subset analysis, belatacept-treated patients with CNS PTLD, CNS <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> including PML, other serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, and malignancies were observed to have a higher incidence of IgG concentrations below the lower limit of the normal range (&lt;694 mg/dL) at Month 6 than those patients who did not experience these adverse events. This observation was more pronounced with the higher than recommended dose of belatacept. A similar trend was also observed for cyclosporine-treated patients with serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> and malignancies.</p>
<p>However, it is unclear whether any causal relationship between an IgG concentration below the lower level of normal and these adverse events exists, as the analysis may have been confounded by other factors (e.g., age greater than 60 years, receipt of an extended criteria donor kidney, exposure to lymphocyte depleting agents) which were also associated with IgG below the lower level of normal at Month 6 in these trials.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="s12.3"></a><a name="section-11.3"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First">Table 5 summarizes the pharmacokinetic parameters of belatacept in healthy adult subjects after a single 10 mg per kg intravenous infusion; and in kidney transplant patients after the 10 mg per kg intravenous infusion at Week 12, and after 5 mg per kg intravenous infusion every 4 weeks at Month 12 post-transplant or later.</p>
<table cellpadding="4.8pt" width="100%">
<caption><span>Table 5: Pharmacokinetic Parameters (Mean±SD [Range]) of Belatacept in Healthy Subjects and Kidney Transplant Patients After 5 and 10 mg per kg Intravenous Infusions Administered Over 30 Minutes</span></caption>
<col width="31%">
<col width="23%">
<col width="23%">
<col width="22%">
<thead><tr class="First Last">
<th class="Botrule Lrule Rrule Toprule" align="left" valign="top"><span class="Bold">Pharmacokinetic Parameter</span></th>
<th class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<span class="Bold">Healthy Subjects</span><br><br><span class="Bold">(After 10 mg per kg</span><br><span class="Bold">Single Dose)</span><br><span class="Bold">N=15</span>
</th>
<th class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<span class="Bold">Kidney Transplant</span><br><span class="Bold">Patients</span><br><span class="Bold">(After 10 mg per kg</span><br><span class="Bold">Multiple Doses)</span><br><span class="Bold">N=10</span>
</th>
<th class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<span class="Bold">Kidney Transplant</span><br><span class="Bold">Patients</span><br><span class="Bold">(After 5 mg per kg</span><br><span class="Bold">Multiple Doses)</span><br><span class="Bold">N=14</span>
</th>
</tr></thead>
<tfoot><tr class="First Last"><td class="Botrule" align="left" colspan="4" valign="top">* AUC=AUC (INF) after single dose and AUC (TAU) after multiple dose, where TAU=4 weeks</td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule Toprule"><p class="First">Peak concentration (C<span class="Sub">max</span>) [µg/mL]</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">300±77<br>(190-492)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">247±68<br>(161-340)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">139±28<br>(80-176)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">AUC*<br>[μg•h/mL]</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">26398±5175<br>(18964-40684)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">22252±7868<br>(13575-42144)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">14090±3860<br>(7906-20510)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Terminal half-life (t<span class="Sub">1/2</span>) [days] </p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">9.8±2.8<br>(6.4-15.6)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">9.8±3.2<br>(6.1-15.1)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">8.2±2.4<br>(3.1-11.9)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Systemic clearance (CL) [mL/h/kg] </p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.39±0.07<br>(0.25-0.53)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.49±0.13<br>(0.23-0.70)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.51±0.14<br>(0.33-0.75)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule"><p class="First">Volume of distribution (Vss) [L/kg] </p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.09±0.02<br>(0.07-0.15)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.11±0.03<br>(0.067-0.17)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.12±0.03<br>(0.09-0.17)</p></td>
</tr>
</tbody>
</table>
<p>In healthy subjects, the pharmacokinetics of belatacept was linear and the exposure to belatacept increased proportionally after a single intravenous infusion dose of 1 to 20 mg per kg. The pharmacokinetics of belatacept in <span class="Italics">de novo</span> kidney transplant patients and healthy subjects are comparable. Following the recommended regimen, the mean belatacept serum concentration reached steady-state by Week 8 in the initial phase following transplantation and by Month 6 during the maintenance phase. Following once monthly intravenous infusion of 10 mg per kg and 5 mg per kg, there was about 20% and 10% systemic accumulation of belatacept in kidney transplant patients, respectively.</p>
<p>Based on population pharmacokinetic analysis of 924 kidney transplant patients up to 1 year post-transplant, the pharmacokinetics of belatacept were similar at different time periods post-transplant. In clinical trials, trough concentrations of belatacept were consistently maintained from Month 6 up to 3 years post-transplant. Population pharmacokinetic analyses in kidney transplant patients revealed that there was a trend toward higher clearance of belatacept with increasing body weight. Age, gender, race, renal function (measured by calculated glomerular filtration rate [GFR]), hepatic function (measured by albumin), <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, and concomitant dialysis did not affect the clearance of belatacept.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_bace6de0-d43c-4ff7-baf7-6902460bdae1"></a><a name="section-11.3.1"></a><p></p>
<h3>Drug Interactions</h3>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_f35817ea-3848-4a9d-bda5-6c988c06605b"></a><a name="section-11.3.1.1"></a><p></p>
<h4>Mycophenolate Mofetil</h4>
<p class="First">In a pharmacokinetic substudy of Studies 1 and 2, the plasma concentrations of MPA were measured in 41 patients who received fixed MMF doses of 500 to 1500 mg twice daily with either 5 mg per kg of NULOJIX or cyclosporine. The mean dose-normalized MPA C<span class="Sub">max</span> and AUC<span class="Sub">0-12</span> were approximately 20% and 40% higher, respectively, with NULOJIX coadministration than with cyclosporine coadministration [see <span class="Italics"><a href="#s7.1">Drug Interactions (7.1)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_23c68d6a-3b3f-48c9-984d-97c00e1214df"></a><a name="section-11.3.1.2"></a><p></p>
<h4>Cytochrome P450 Substrates</h4>
<p class="First">The potential of NULOJIX to alter the systemic concentrations of drugs that are CYP450 substrates was investigated in healthy subjects following administration of a cocktail of probe drugs given concomitantly with, and at 3 days and at 7 days following a single intravenous 10 mg per kg dose of NULOJIX. NULOJIX did not alter the pharmacokinetics of drugs that are substrates of CYP1A2 (caffeine), CYP2C9 (losartan), CYP2D6 (dextromethorphan), CYP3A (midazolam), and CYP2C19 (omeprazole) [see <span class="Italics"><a href="#s7.2">Drug Interactions (7.2)</a></span>].</p>
</div>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="s13"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="s13.1"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">A carcinogenicity study was not conducted with belatacept. However, a murine carcinogenicity study was conducted with abatacept (a more active analog in rodents) to determine the carcinogenic potential of CD28 blockade. Weekly subcutaneous injections of 20, 65, or 200 mg per kg of abatacept were associated with increases in the incidence of <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">malignant lymphomas</span> (all doses) and mammary gland tumors (intermediate- and high-dose in females) at clinically relevant exposures. The mice in this study were infected with endogenous murine <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">leukemia</span> and mouse mammary tumor viruses which are associated with an increased incidence of <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphomas</span> and mammary gland tumors, respectively, in immunosuppressed mice. Although the precise relevance of these findings to the clinical use of NULOJIX is unknown, cases of PTLD (a premalignant or malignant proliferation of B <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span>) were reported in clinical trials.</p>
<p>Genotoxicity testing is not required for protein therapeutics; therefore, no genotoxicity studies were conducted with belatacept.</p>
<p>Belatacept had no adverse effects on male or female fertility in rats at doses up to 200 mg per kg daily (25 times the MRHD exposure).</p>
</div>
<div class="Section" data-sectionCode="34091-9">
<a name="s13.2"></a><a name="section-12.2"></a><p></p>
<h2>13.2 Animal Toxicology and/or Pharmacology</h2>
<p class="First">Abatacept, a fusion protein that differs from belatacept by 2 amino acids, binds to the same ligands (CD80/CD86) and blocks T-cell costimulation like belatacept, but is more active than belatacept in rodents. Therefore, toxicities identified with abatacept in rodents may be predictive of adverse effects in humans treated with belatacept.</p>
<p>Studies in rats exposed to abatacept have shown immune system abnormalities including a low incidence of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> leading to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> (observed in juvenile rats and pregnant rats) as well as autoimmunity of the thyroid and pancreas (observed in rats exposed <span class="Italics">in utero</span>, as juveniles or as adults). Studies of abatacept in adult mice and monkeys, as well as belatacept in adult monkeys, have not demonstrated similar findings.</p>
<p>The increased susceptibility to <span class="product-label-link" type="condition" conceptid="4247535" conceptname="Opportunistic infectious disease">opportunistic infections</span> observed in juvenile rats is likely associated with the exposure to abatacept before the complete development of memory immune responses. In pregnant rats, the increased susceptibility to <span class="product-label-link" type="condition" conceptid="4247535" conceptname="Opportunistic infectious disease">opportunistic infections</span> may be due to the inherent lapses in immunity that occur in rats during late pregnancy/lactation. <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> related to NULOJIX have been observed in human clinical trials [see <span class="Italics"><a href="#s5.5">Warnings and Precautions (5.5)</a></span>].</p>
<p>Administration of abatacept to rats was associated with a significant decrease in T-regulatory cells (up to 90%). Deficiency of T-regulatory cells in humans has been associated with autoimmunity. The occurrence of autoimmune events across the core clinical trials was infrequent. However, the possibility that patients administered NULOJIX could develop autoimmunity (or that fetuses exposed to NULOJIX <span class="Italics">in utero</span> could develop autoimmunity) cannot be excluded.</p>
<p>In a 6-month toxicity study with belatacept in cynomolgus monkeys administered weekly doses up to 50 mg per kg (6 times the MRHD exposure) and in a 1-year toxicity study with abatacept in adult cynomolgus monkeys administered weekly doses up to 50 mg per kg, no significant drug-related toxicities were observed. Reversible pharmacological effects consisted of minimal transient decreases in serum IgG and minimal to severe lymphoid depletion of germinal centers in the spleen and/or lymph nodes.</p>
<p>Following 5 doses (10 mg per kg or 50 mg per kg, once a week for 5 weeks) of systemic administration, belatacept was not detected in brain tissue of normal healthy cynomolgus monkeys. The number of cells expressing major histocompatibility complex (MHC) class-II antigens (potential marker of immune cell activation) in the brain were increased in monkeys administered belatacept compared to vehicle control. However, distribution of some other cells expressing CD68, CD20, CD80, and CD86, typically expressed on MHC class II-positive cells, was not altered and there were no other histological changes in the brain. The clinical relevance of the findings is unknown.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="s14"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s14.1"></a><a name="section-13.1"></a><p></p>
<h2>14.1 Prevention of Organ Rejection in Kidney Transplant Recipients</h2>
<p class="First">The efficacy and safety of NULOJIX in <span class="Italics">de novo</span> kidney transplantation were assessed in two open-label, randomized, multicenter, active-controlled trials (Study 1 and Study 2). These trials evaluated two dose regimens of NULOJIX, the recommended dosage regimen [see <span class="Italics"><a href="#s2.1">Dosage and Administration (2.1)</a></span>] and a regimen with higher cumulative doses and more frequent dosing than the recommended dosage regimen, compared to a cyclosporine control regimen. All treatment groups also received basiliximab induction, mycophenolate mofetil (MMF), and corticosteroids.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s14.1.1"></a><a name="section-13.1.1"></a><p></p>
<h3>Treatment Regimen</h3>
<p class="First">The NULOJIX recommended regimen consisted of a 10 mg per kg dose administered on Day 1 (the day of transplantation, prior to implantation), Day 5 (approximately 96 hours after the Day 1 dose), end of Weeks 2 and 4; then every 4 weeks through Week 12 after transplantation. Starting at Week 16 after transplantation, NULOJIX was administered at the maintenance dose of 5 mg per kg every 4 weeks (plus or minus 3 days). NULOJIX was administered as an intravenous infusion over 30 minutes [see <span class="Italics"><a href="#s2.1">Dosage and Administration (2.1)</a></span>].</p>
<p>Basiliximab 20 mg was administered intravenously on the day of transplantation and 4 days later.</p>
<p>The initial dose of MMF was 1 gram twice daily and was adjusted, as needed based on clinical signs of adverse events or efficacy failure.</p>
<p>The protocol-specified dosing of corticosteroids in Studies 1 and 2 at Day 1 was methylprednisolone (as sodium succinate) 500 mg IV on arrival in the operating room, Day 2, methylprednisolone 250 mg IV, and Day 3, prednisone 100 mg orally. Actual median corticosteroid doses used with the NULOJIX recommended regimen from Week 1 through Month 6 are summarized in the table below (Table 6).</p>
<table cellpadding="2.4pt" width="97.9%">
<caption><span>Table 6: Actual Corticosteroid* Dosing in Studies 1 and 2</span></caption>
<col width="33%">
<col width="33%">
<col width="33%">
<thead>
<tr class="First">
<th class="Lrule Rrule Toprule" align="center" valign="top"><span class="Bold">Day of Dosing</span></th>
<th class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="top"><span class="Bold">Median (Q1–Q3) Daily Dose<span class="Sup">†,‡</span></span></th>
</tr>
<tr class="Last">
<th class="Botrule Lrule Rrule" align="left" valign="top"></th>
<th class="Botrule Lrule Rrule" align="center" valign="top"><span class="Bold">Study 1</span></th>
<th class="Botrule Lrule Rrule" align="center" valign="top"><span class="Bold">Study 2</span></th>
</tr>
</thead>
<tfoot><tr class="First Last"><td class="Botrule" align="left" colspan="3" valign="top">*   Corticosteroid = prednisone or prednisolone.<br><span class="Sup">†</span>   The protocols allowed for flexibility in determining corticosteroid dose and rapidity of taper after Day 15. It is not possible to distinguish corticosteroid doses used to treat acute rejection versus doses used in a maintenance regimen.<br><span class="Sup">‡</span>   Q1 and Q3 are the 25<span class="Sup">th</span> and 75<span class="Sup">th</span> percentiles of daily corticosteroid doses, respectively.</td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">Week 1</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">31.7 mg (26.7-50 mg)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">30 mg (26.7-50 mg)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><p class="First">Week 2</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">25 mg (20-30 mg)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">25 mg (20-30 mg)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><p class="First">Week 4</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">20 mg (15-20 mg)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">20 mg (15-22.5 mg)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><p class="First">Week 6</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">15 mg (10-20 mg)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">16.7 mg (12.5-20 mg)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="center"><p class="First">Month 6</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">10 mg (5-10 mg)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">10 mg (5-12.5 mg)</p></td>
</tr>
</tbody>
</table>
<p>Study 1 enrolled recipients of living donor and standard criteria deceased donor organs and Study 2 enrolled recipients of extended criteria donor organs. Standard criteria donor organs were defined as organs from a deceased donor with anticipated <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span> <span class="product-label-link" type="condition" conceptid="4200991" conceptname="Ischemia">ischemia</span> time of &lt;24 hours and not meeting the definition of extended criteria donor organs. Extended criteria donors were defined as deceased donors with at least one of the following: (1) donor age ≥60 years; (2) donor age ≥50 years and other donor comorbidities (≥2 of the following: <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, serum creatinine &gt;1.5 mg/dL); (3) donation of organ after cardiac <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>; or (4) anticipated <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span> <span class="product-label-link" type="condition" conceptid="4200991" conceptname="Ischemia">ischemia</span> time of the organ of ≥24 hours. Study 1 excluded recipients undergoing a first transplant whose current Panel Reactive Antibodies (PRA) were ≥50% and recipients undergoing a retransplantation whose current PRA were ≥30%; Study 2 excluded recipients with a current PRA ≥30%. Both studies excluded recipients with HIV, <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> C, or evidence of current <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>; recipients with active <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span>; and recipients in whom intravenous access was difficult to obtain.</p>
<p>Efficacy data are presented for the NULOJIX recommended regimen and cyclosporine regimen in Studies 1 and 2.</p>
<p>The NULOJIX regimen with higher cumulative doses and more frequent dosing of belatacept was associated with more efficacy failures. Higher doses and/or more frequent dosing of NULOJIX are not recommended [see <span class="Italics"><a href="#s2.1">Dosage and Administration (2.1)</a></span>, <span class="Italics"><a href="#s5.1">Warnings and Precautions (5.1)</a></span>, and <span class="Italics"><a href="#s6.1">Adverse Reactions (6.1)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s14.1.2"></a><a name="section-13.1.2"></a><p></p>
<h3>Study 1: Recipients of Living Donor and Standard Criteria Deceased Donor Kidneys</h3>
<p class="First">In Study 1, 666 patients were enrolled, randomized, and transplanted: 226 to the NULOJIX recommended regimen, 219 to the NULOJIX regimen with higher cumulative doses and more frequent dosing than recommended, and 221 to cyclosporine control regimen. The median age was 45 years; 58% of organs were from living donors; 3% were re-transplanted; 69% of the study population was male; 61% of patients were white, 8% were black/African-American, 31% were categorized as of other races; 16% had PRA ≥10%; 41% had 4 to 6 HLA mismatches; and 27% had <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> prior to transplant. The incidence of delayed graft function was similar in all treatment arms (14% to 18%).</p>
<p>Premature discontinuation from treatment at the end of the first year occurred in 19% of patients receiving the NULOJIX recommended regimen and 19% of patients on the cyclosporine regimen. Among the patients who received the NULOJIX recommended regimen, 10% discontinued due to lack of efficacy, 5% due to adverse events, and 4% for other reasons. Among the patients who received the cyclosporine regimen, 9% discontinued due to adverse events, 5% due to lack of efficacy, and 5% for other reasons.</p>
<p>At the end of three years, 25% of patients receiving the NULOJIX recommended regimen and 34% of patients receiving the cyclosporine regimen had discontinued from treatment. Among the patients who received the NULOJIX recommended regimen, 12% discontinued due to lack of efficacy, 7% due to adverse events, and 6% for other reasons. Among the patients who received the cyclosporine regimen, 15% discontinued due to adverse events, 8% due to lack of efficacy, and 11% for other reasons.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s14.1.2.1"></a><a name="section-13.1.2.1"></a><p></p>
<h4>Assessment of Efficacy</h4>
<p class="First">Table 7 summarizes the results of Study 1 following one and three years of treatment with the NULOJIX recommended dosage regimen and the cyclosporine control regimen. Efficacy failure at one year was defined as the occurrence of biopsy proven acute rejection (BPAR), graft loss, <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, or lost to follow-up. BPAR was defined as histologically confirmed acute rejection by a central pathologist on a biopsy done for any reason, whether or not accompanied by clinical signs of rejection. Patient and graft survival was also assessed separately.</p>
<table cellpadding="4.8pt" width="97.06%">
<caption><span>Table 7: Efficacy Outcomes by Years 1 and 3 for Study 1: Recipients of Living and Standard Criteria Deceased Donor Kidneys</span></caption>
<col width="34%">
<col width="22%">
<col width="22%">
<col width="22%">
<thead><tr class="First Last">
<th class="Botrule Lrule Rrule Toprule" align="left" valign="top"><span class="Bold">Parameter</span></th>
<th class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<span class="Bold">NULOJIX</span><br><span class="Bold">Recommended Regimen</span><br><span class="Bold">N=226</span><br><span class="Bold">n (%)</span>
</th>
<th class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<span class="Bold">Cyclosporine</span><br><span class="Bold">CSA</span><br><span class="Bold">N=221</span><br><span class="Bold">n (%)</span>
</th>
<th class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<span class="Bold">NULOJIX-CSA</span><br><br><span class="Bold">(97.3% CI)</span>
</th>
</tr></thead>
<tfoot><tr class="First Last"><td class="Botrule" align="left" colspan="4" valign="top">*  Patients may have experienced more than one event.<br><span class="Sup">†</span>  Patients known to be alive with a functioning graft.</td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Lrule Rrule Toprule"><p class="First">Efficacy Failure by Year 1</p></td>
<td class="Lrule Rrule Toprule" align="center"><p class="First">49 (21.7)</p></td>
<td class="Lrule Rrule Toprule" align="center"><p class="First">37 (16.7)</p></td>
<td class="Lrule Rrule Toprule" align="center"><p class="First">4.9 (−3.3, 13.2)</p></td>
</tr>
<tr>
<td class="Lrule Rrule"><p class="First">   Components of Efficacy Failure*</p></td>
<td class="Lrule Rrule"></td>
<td class="Lrule Rrule"></td>
<td class="Lrule Rrule"></td>
</tr>
<tr>
<td class="Lrule Rrule"><p class="First">       Biopsy Proven Acute Rejection</p></td>
<td class="Lrule Rrule" align="center"><p class="First">45 (19.9)</p></td>
<td class="Lrule Rrule" align="center"><p class="First">23 (10.4)</p></td>
<td class="Lrule Rrule" align="center"><p class="First"> </p></td>
</tr>
<tr>
<td class="Lrule Rrule"><p class="First">       Graft Loss</p></td>
<td class="Lrule Rrule" align="center"><p class="First">5 (2.2)</p></td>
<td class="Lrule Rrule" align="center"><p class="First">8 (3.6)</p></td>
<td class="Lrule Rrule" align="center"><p class="First"> </p></td>
</tr>
<tr>
<td class="Lrule Rrule"><p class="First">       <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span></p></td>
<td class="Lrule Rrule" align="center"><p class="First">4 (1.8)</p></td>
<td class="Lrule Rrule" align="center"><p class="First">7 (3.2)</p></td>
<td class="Lrule Rrule" align="center"><p class="First"> </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">       Lost to follow-up</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">1 (0.5)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First"> </p></td>
</tr>
<tr>
<td class="Lrule Rrule"><p class="First">Efficacy Failure by Year 3</p></td>
<td class="Lrule Rrule" align="center"><p class="First">58 (25.7)</p></td>
<td class="Lrule Rrule" align="center"><p class="First">57 (25.8)</p></td>
<td class="Lrule Rrule" align="center"><p class="First">−0.1 (−9.3, 9)</p></td>
</tr>
<tr>
<td class="Lrule Rrule"><p class="First">   Components of Efficacy Failure*</p></td>
<td class="Lrule Rrule"></td>
<td class="Lrule Rrule"></td>
<td class="Lrule Rrule"></td>
</tr>
<tr>
<td class="Lrule Rrule"><p class="First">       Biopsy Proven Acute Rejection</p></td>
<td class="Lrule Rrule" align="center"><p class="First">50 (22.1)</p></td>
<td class="Lrule Rrule" align="center"><p class="First">31 (14)</p></td>
<td class="Lrule Rrule" align="center"><p class="First"> </p></td>
</tr>
<tr>
<td class="Lrule Rrule"><p class="First">       Graft Loss</p></td>
<td class="Lrule Rrule" align="center"><p class="First">9 (4)</p></td>
<td class="Lrule Rrule" align="center"><p class="First">10 (4.5)</p></td>
<td class="Lrule Rrule" align="center"><p class="First"> </p></td>
</tr>
<tr>
<td class="Lrule Rrule"><p class="First">       <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span></p></td>
<td class="Lrule Rrule" align="center"><p class="First">10 (4.4)</p></td>
<td class="Lrule Rrule" align="center"><p class="First">15 (6.8)</p></td>
<td class="Lrule Rrule" align="center"><p class="First"> </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">       Lost to follow-up</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">2 (0.9)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">5 (2.3)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First"> </p></td>
</tr>
<tr>
<td class="Lrule Rrule"><p class="First">Patient and graft survival<span class="Sup">†</span></p></td>
<td class="Lrule Rrule" align="center"><p class="First"> </p></td>
<td class="Lrule Rrule" align="center"><p class="First"> </p></td>
<td class="Lrule Rrule" align="center"><p class="First"> </p></td>
</tr>
<tr>
<td class="Lrule Rrule"><p class="First">Year 1</p></td>
<td class="Lrule Rrule" align="center"><p class="First">218 (96.5)</p></td>
<td class="Lrule Rrule" align="center"><p class="First">206 (93.2)</p></td>
<td class="Lrule Rrule" align="center"><p class="First">3.2 (−1.5, 8.4)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule"><p class="First">Year 3</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">206 (91.2)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">192 (86.9)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">4.3 (−2.2, 10.8)</p></td>
</tr>
</tbody>
</table>
<p>In Study 1, the rate of BPAR at one year and three years was higher in patients treated with the NULOJIX recommended regimen than the cyclosporine regimen. Of the patients who experienced BPAR with NULOJIX, 70% experienced BPAR by Month 3, and 84% experienced BPAR by Month 6. By three years, recurrent BPAR occurred with similar frequency across treatment groups (&lt;3%). The component of BPAR determined by biopsy only (subclinical protocol-defined acute rejection) was 5% in both treatment groups.</p>
<p>Patients treated with the NULOJIX recommended regimen experienced episodes of BPAR classified as Banff grade IIb or higher (6% [14/226] at one year and 7% [15/226] at three years) more frequently compared to patients treated with the cyclosporine regimen (2% [4/221] at one year and 2% [5/221] at three years). Also, T-cell depleting therapy was used more frequently to treat episodes of BPAR in NULOJIX-treated patients (10%; 23/226) compared to cyclosporine-treated patients (2%; 5/221). At Month 12, the difference in mean calculated glomerular filtration rate (GFR) between patients with and without history of BPAR was 19 mL/min/1.73 m<span class="Sup">2</span> among NULOJIX-treated patients compared to 7 mL/min/1.73 m<span class="Sup">2</span> among cyclosporine-treated patients. By three years, 22% (11/50) of NULOJIX-treated patients with a history of BPAR experienced graft loss and/or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> compared to 10% (3/31) of cyclosporine-treated patients with a history of BPAR; at that time point, 10% (5/50) of NULOJIX-treated patients experienced graft loss and 12% (6/50) of NULOJIX-treated patients had died following an episode of BPAR, whereas 7% (2/31) of cyclosporine-treated patients experienced graft loss and 7% (2/31) of cyclosporine-treated patients had died following an episode of BPAR. The overall prevalence of donor-specific antibodies was 5% and 11% for the NULOJIX recommended regimen and cyclosporine, respectively, up to 36 months post-transplant.</p>
<p>While the difference in GFR in patients with BPAR versus those without BPAR was greater in patients treated with NULOJIX than cyclosporine, the mean GFR following BPAR was similar in NULOJIX (49 mL/min/1.73 m<span class="Sup">2</span>) and cyclosporine treated patients (43 mL/min/1.73 m<span class="Sup">2</span>) at one year. The relationship between BPAR, GFR, and patient and graft survival is unclear due to the limited number of patients who experienced BPAR, differences in renal hemodynamics (and, consequently, GFR) across maintenance <span class="product-label-link" type="condition" conceptid="4242843" conceptname="Immunosuppression">immunosuppression</span> regimens, and the high rate of switching treatment regimens after BPAR.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s14.1.2.2"></a><a name="section-13.1.2.2"></a><p></p>
<h4>Assessment of Efficacy in the EBV Seropositive Subpopulation</h4>
<p class="First">NULOJIX is recommended for use only in EBV seropositive patients [see <span class="Italics"><a href="#s1.2">Indications and Usage (1.2)</a></span>].</p>
<p>In Study 1, approximately 87% of patients were EBV seropositive prior to transplant. Efficacy results in the EBV seropositive subpopulation were consistent with those in the total population studied.</p>
<p>By one year, the efficacy failure rate in the EBV seropositive population was 21% (42/202) in patients treated with the NULOJIX recommended regimen and 17% (31/184) in patients treated with cyclosporine (difference=4%, 97.3% CI [−4.8, 12.8]). Patient and graft survival was 98% (198/202) in NULOJIX-treated patients and 92% (170/184) in cyclosporine-treated patients (difference=5.6%, 97.3% CI [0.8, 10.4]).</p>
<p>By three years, efficacy failure was 25% in both treatment groups and patient and graft survival was 94% (187/202) in NULOJIX-treated patients compared with 88% (162/184) in cyclosporine-treated patients (difference=4.6%, 97.3% CI [−2.1, 11.3]).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s14.1.2.3"></a><a name="section-13.1.2.3"></a><p></p>
<h4>Assessment of Glomerular Filtration Rate (GFR)</h4>
<p class="First">Glomerular Filtration Rate (GFR) was measured at one and two years and was calculated using the Modification of Diet in <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">Renal Disease</span> (MDRD) formula at one, two, and three years after transplantation. As shown in Table 8, both measured and calculated GFR was higher in patients treated with the NULOJIX recommended regimen compared to patients treated with the cyclosporine control regimen at all time points. As shown in Figure 1, the differences in GFR were apparent in the first month after transplant and were maintained up to three years (36 months). An analysis of change of calculated mean GFR between three and 36 months demonstrated an increase of 0.8 mL/min/year (95% CI [−0.2, 1.8]) for NULOJIX-treated patients and a decrease of 2.2 mL/min/year (95% CI [−3.2, −1.2]) for cyclosporine-treated patients.</p>
<table cellpadding="4.8pt" width="100%">
<caption><span>Table 8: Measured and Calculated GFR for Study 1: Recipients of Living and Standard Criteria Deceased Donor Kidneys</span></caption>
<col width="39%">
<col width="23%">
<col width="19%">
<col width="19%">
<thead><tr class="First Last">
<th class="Botrule Lrule Rrule Toprule" align="left" valign="top"><span class="Bold">Parameter</span></th>
<th class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<span class="Bold">NULOJIX</span><br><span class="Bold">Recommended Regimen</span><br><span class="Bold">N=226</span>
</th>
<th class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<span class="Bold">Cyclosporine</span><br><span class="Bold">(CSA)</span><br><span class="Bold">N=221</span>
</th>
<th class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<span class="Bold">NULOJIX-CSA</span><br><br><span class="Bold">(97.3% CI)</span>
</th>
</tr></thead>
<tfoot><tr class="First Last"><td class="Botrule" align="left" colspan="4" valign="top">*  GFR was measured using the <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span>-iothalamate method.<br><span class="Sup">†</span>  Measured GFR was not assessed at Year 3.<br><span class="Sup">‡</span>  GFR was calculated using the MDRD formula.</td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Lrule Rrule Toprule"><p class="First">Measured GFR* mL/min/1.73 m<span class="Sup">2</span> mean (SD)</p></td>
<td class="Lrule Rrule Toprule" align="center"><p class="First"> </p></td>
<td class="Lrule Rrule Toprule" align="center"><p class="First"> </p></td>
<td class="Lrule Rrule Toprule" align="center"><p class="First"> </p></td>
</tr>
<tr>
<td class="Lrule Rrule"><p class="First">Year 1</p></td>
<td class="Lrule Rrule" align="center"><p class="First">63.4 (27.7)</p></td>
<td class="Lrule Rrule" align="center"><p class="First">50.4 (18.7)</p></td>
<td class="Lrule Rrule" align="center"><p class="First">13.0 (7.3, 18.7)</p></td>
</tr>
<tr>
<td class="Lrule Rrule" align="center"><p class="First"> </p></td>
<td class="Lrule Rrule" align="center"><p class="First">(n=206)</p></td>
<td class="Lrule Rrule" align="center"><p class="First">(n=199)</p></td>
<td class="Lrule Rrule" align="center"><p class="First"> </p></td>
</tr>
<tr>
<td class="Lrule Rrule"><p class="First">Year 2<span class="Sup">†</span></p></td>
<td class="Lrule Rrule" align="center"><p class="First">67.9 (29.9)</p></td>
<td class="Lrule Rrule" align="center"><p class="First">50.5 (20.5)</p></td>
<td class="Lrule Rrule" align="center"><p class="First">17.4 (11.5, 23.4)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><p class="First"> </p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">(n=199)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">(n=185)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First"> </p></td>
</tr>
<tr>
<td class="Lrule Rrule Toprule"><p class="First">Calculated GFR<span class="Sup">‡</span> mL/min/1.73 m<span class="Sup">2</span> mean (SD)</p></td>
<td class="Lrule Rrule Toprule" align="center"><p class="First"> </p></td>
<td class="Lrule Rrule Toprule" align="center"><p class="First"> </p></td>
<td class="Lrule Rrule Toprule" align="center"><p class="First"> </p></td>
</tr>
<tr>
<td class="Lrule Rrule"><p class="First">Year 1</p></td>
<td class="Lrule Rrule" align="center"><p class="First">65.4 (22.9)</p></td>
<td class="Lrule Rrule" align="center"><p class="First">50.1 (21.1)</p></td>
<td class="Lrule Rrule" align="center"><p class="First">15.3 (10.3, 20.3)</p></td>
</tr>
<tr>
<td class="Lrule Rrule" align="center"><p class="First"> </p></td>
<td class="Lrule Rrule" align="center"><p class="First">(n=200)</p></td>
<td class="Lrule Rrule" align="center"><p class="First">(n=199)</p></td>
<td class="Lrule Rrule" align="center"><p class="First"> </p></td>
</tr>
<tr>
<td class="Lrule Rrule"><p class="First">Year 2</p></td>
<td class="Lrule Rrule" align="center"><p class="First">65.4 (25.2)</p></td>
<td class="Lrule Rrule" align="center"><p class="First">47.9 (23)</p></td>
<td class="Lrule Rrule" align="center"><p class="First">17.5 (12, 23.1)</p></td>
</tr>
<tr>
<td class="Lrule Rrule" align="center"><p class="First"> </p></td>
<td class="Lrule Rrule" align="center"><p class="First">(n=201)</p></td>
<td class="Lrule Rrule" align="center"><p class="First">(n=182)</p></td>
<td class="Lrule Rrule" align="center"><p class="First"> </p></td>
</tr>
<tr>
<td class="Lrule Rrule"><p class="First">Year 3</p></td>
<td class="Lrule Rrule" align="center"><p class="First">65.8 (27)</p></td>
<td class="Lrule Rrule" align="center"><p class="First">44.4 (23.6)</p></td>
<td class="Lrule Rrule" align="center"><p class="First">21.4 (15.4, 27.4)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="center"><p class="First"> </p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">(n=190)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">(n=171)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First"> </p></td>
</tr>
</tbody>
</table>
<p><span class="Bold">Figure 1: Calculated (MDRD) GFR through Month 36; Study 1: Recipients of Living and Standard Criteria Deceased Donor Kidneys</span></p>
<div class="Figure">
<a name="id2143"></a><img alt="Figure 1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c16ac648-d5d2-9f7d-8637-e2328572754e&amp;name=figure1.jpg">
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s14.1.2.4"></a><a name="section-13.1.2.4"></a><p></p>
<h4>Assessment of <span class="product-label-link" type="condition" conceptid="4032423" conceptname="Transplant glomerulopathy">Chronic Allograft Nephropathy</span> (CAN)</h4>
<p class="First">The prevalence of <span class="product-label-link" type="condition" conceptid="4032423" conceptname="Transplant glomerulopathy">chronic allograft nephropathy</span> (CAN) at one year, as defined by the Banff ’97 classification system, was 24% (54/226) in patients treated with the NULOJIX recommended regimen and in 32% (71/219) of patients treated with the cyclosporine control regimen. CAN was not evaluated after the first year following transplantation. The clinical significance of this finding is unknown.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s14.1.3"></a><a name="section-13.1.3"></a><p></p>
<h3>Study 2: Recipients of Extended Criteria Donor Kidneys</h3>
<p class="First">In Study 2, 543 patients were enrolled, randomized, and transplanted: 175 to the NULOJIX recommended regimen, 184 to the NULOJIX regimen with higher cumulative doses and more frequent dosing than recommended, and 184 to the cyclosporine control regimen. The median age was 58 years; 67% of the study population was male; 75% of patients were white, 13% were black/African-American, 12% were categorized as of other races; 3% had PRA ≥10%; 53% had 4 to 6 HLA mismatches; and 29% had <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> prior to transplantation. The incidence of delayed graft function was similar in all treatment arms (47% to 49%).</p>
<p>Premature discontinuation from treatment at the end of the first year occurred in 25% of patients receiving the NULOJIX recommended regimen and 30% of patients receiving the cyclosporine control regimen. Among the patients who received the NULOJIX recommended regimen, 14% discontinued due to adverse events, 9% due to lack of efficacy, and 2% for other reasons. Among the patients who received the cyclosporine regimen, 17% discontinued due to adverse events, 7% due to lack of efficacy, and 6% for other reasons.</p>
<p>At the end of three years, 35% of patients receiving the NULOJIX recommended regimen and 44% of patients receiving the cyclosporine regimen had discontinued from treatment. Among the patients who received the NULOJIX recommended regimen, 20% discontinued due to adverse events, 9% due to lack of efficacy, and 6% for other reasons. Among the patients who received the cyclosporine regimen, 25% discontinued due to adverse events, 10% due to lack of efficacy, and 10% for other reasons.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s14.1.3.1"></a><a name="section-13.1.3.1"></a><p></p>
<h4>Assessment of Efficacy</h4>
<p class="First">Table 9 summarizes the results of Study 2 following one and three years of treatment with the NULOJIX recommended dosage regimen and the cyclosporine control regimen. Efficacy failure at one year was defined as the occurrence of biopsy proven acute rejection (BPAR), graft loss, <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, or lost to follow-up. BPAR was defined as histologically confirmed acute rejection by a central pathologist on a biopsy done for any reason, whether or not accompanied by clinical signs of rejection. Patient and graft survival was also assessed.</p>
<table cellpadding="4.8pt" width="100%">
<caption><span>Table 9: Efficacy Outcomes by Years 1 and 3 for Study 2: Recipients of Extended Criteria Donor Kidneys</span></caption>
<col width="34%">
<col width="22%">
<col width="22%">
<col width="22%">
<thead><tr class="First Last">
<th class="Botrule Lrule Rrule Toprule" align="left" valign="top"><span class="Bold">Parameter</span></th>
<th class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<span class="Bold">NULOJIX</span><br><span class="Bold">Recommended Regimen</span><br><span class="Bold">N=175</span><br><span class="Bold">n (%)</span>
</th>
<th class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<span class="Bold">Cyclosporine</span><br><span class="Bold">(CSA)</span><br><span class="Bold">N=184</span><br><span class="Bold">n (%)</span>
</th>
<th class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<span class="Bold">NULOJIX-CSA</span><br><br><span class="Bold">(97.3% CI)</span>
</th>
</tr></thead>
<tfoot><tr class="First Last"><td class="Botrule" align="left" colspan="4" valign="top">*  Patients may have experienced more than one event.<br><span class="Sup">†</span>  Patients known to be alive with a functioning graft.</td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Lrule Rrule Toprule"><p class="First">Efficacy Failure by Year 1</p></td>
<td class="Lrule Rrule Toprule" align="center"><p class="First">51 (29.1)</p></td>
<td class="Lrule Rrule Toprule" align="center"><p class="First">52 (28.3)</p></td>
<td class="Lrule Rrule Toprule" align="center"><p class="First">0.9 (−9.7, 11.5)</p></td>
</tr>
<tr>
<td class="Lrule Rrule"><p class="First">   Components of Efficacy Failure*</p></td>
<td class="Lrule Rrule" align="center"><p class="First"> </p></td>
<td class="Lrule Rrule" align="center"><p class="First"> </p></td>
<td class="Lrule Rrule" align="center"><p class="First"> </p></td>
</tr>
<tr>
<td class="Lrule Rrule"><p class="First">       Biopsy Proven Acute Rejection </p></td>
<td class="Lrule Rrule" align="center"><p class="First">37 (21.1)</p></td>
<td class="Lrule Rrule" align="center"><p class="First">34 (18.5)</p></td>
<td class="Lrule Rrule" align="center"><p class="First"> </p></td>
</tr>
<tr>
<td class="Lrule Rrule"><p class="First">       Graft Loss</p></td>
<td class="Lrule Rrule" align="center"><p class="First">16 (9.1)</p></td>
<td class="Lrule Rrule" align="center"><p class="First">20 (10.9)</p></td>
<td class="Lrule Rrule" align="center"><p class="First"> </p></td>
</tr>
<tr>
<td class="Lrule Rrule"><p class="First">       <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span></p></td>
<td class="Lrule Rrule" align="center"><p class="First">5 (2.9)</p></td>
<td class="Lrule Rrule" align="center"><p class="First">8 (4.3)</p></td>
<td class="Lrule Rrule" align="center"><p class="First"> </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">       Lost to follow-up</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">2 (1.1)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First"> </p></td>
</tr>
<tr>
<td class="Lrule Rrule"><p class="First">Efficacy Failure by Year 3</p></td>
<td class="Lrule Rrule" align="center"><p class="First">63 (36)</p></td>
<td class="Lrule Rrule" align="center"><p class="First">68 (37)</p></td>
<td class="Lrule Rrule" align="center"><p class="First">−1.0 (−12.1, 10.3)</p></td>
</tr>
<tr>
<td class="Lrule Rrule"><p class="First">   Components of Efficacy Failure*</p></td>
<td class="Lrule Rrule" align="center"><p class="First"> </p></td>
<td class="Lrule Rrule" align="center"><p class="First"> </p></td>
<td class="Lrule Rrule" align="center"><p class="First"> </p></td>
</tr>
<tr>
<td class="Lrule Rrule"><p class="First">       Biopsy Proven Acute Rejection </p></td>
<td class="Lrule Rrule" align="center"><p class="First">42 (24)</p></td>
<td class="Lrule Rrule" align="center"><p class="First">42 (22.8)</p></td>
<td class="Lrule Rrule" align="center"><p class="First"> </p></td>
</tr>
<tr>
<td class="Lrule Rrule"><p class="First">       Graft Loss</p></td>
<td class="Lrule Rrule" align="center"><p class="First">21 (12)</p></td>
<td class="Lrule Rrule" align="center"><p class="First">23 (12.5)</p></td>
<td class="Lrule Rrule" align="center"><p class="First"> </p></td>
</tr>
<tr>
<td class="Lrule Rrule"><p class="First">       <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span></p></td>
<td class="Lrule Rrule" align="center"><p class="First">15 (8.6)</p></td>
<td class="Lrule Rrule" align="center"><p class="First">17 (9.2)</p></td>
<td class="Lrule Rrule" align="center"><p class="First"> </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">       Lost to follow-up</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">1 (0.6)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">5 (2.7)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First"> </p></td>
</tr>
<tr>
<td class="Lrule Rrule"><p class="First">Patient and graft survival<span class="Sup">†</span></p></td>
<td class="Lrule Rrule" align="center"><p class="First"> </p></td>
<td class="Lrule Rrule" align="center"><p class="First"> </p></td>
<td class="Lrule Rrule" align="center"><p class="First"> </p></td>
</tr>
<tr>
<td class="Lrule Rrule"><p class="First">Year 1</p></td>
<td class="Lrule Rrule" align="center"><p class="First">155 (88.6)</p></td>
<td class="Lrule Rrule" align="center"><p class="First">157 (85.3)</p></td>
<td class="Lrule Rrule" align="center"><p class="First">3.2 (−4.8, 11.3)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule"><p class="First">Year 3</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">143 (81.7)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">143 (77.7)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">4.0 (−5.4, 13.4)</p></td>
</tr>
</tbody>
</table>
<p>In Study 2, the rate of BPAR at one year and three years was similar in patients treated with NULOJIX and cyclosporine. Of the patients who experienced BPAR with NULOJIX, 62% experienced BPAR by Month 3, and 76% experienced BPAR by Month 6. By three years, recurrent BPAR occurred with similar frequency across treatment groups (&lt;3%). The component of BPAR determined by biopsy only (subclinical protocol-defined acute rejection) was 5% in both treatment groups.</p>
<p>A similar proportion of patients in the NULOJIX recommended regimen group experienced BPAR classified as Banff grade IIb or higher (5% [9/175] at one year and 6% [10/175] at three years) compared to patients treated with the cyclosporine regimen (4% [7/184] at one year and 5% [9/184] at three years). Also, T-cell depleting therapy was used with similar frequency to treat any episode of BPAR in NULOJIX-treated patients (5% or 9/175) compared to cyclosporine-treated patients (4% or 7/184). At Month 12, the difference in mean calculated GFR between patients with and without a history of BPAR was 10 mL/min/1.73 m<span class="Sup">2</span> among NULOJIX-treated patients compared to 14 mL/min/1.73 m<span class="Sup">2</span> among cyclosporine-treated patients. By three years, 24% (10/42) of NULOJIX-treated patients with a history of BPAR experienced graft loss and/or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> compared to 31% (13/42) of cyclosporine-treated patients with a history of BPAR; at that time point, 17% (7/42) of NULOJIX-treated patients experienced graft loss and 14% (6/42) of NULOJIX-treated patients had died following an episode of BPAR, whereas 19% (8/42) of cyclosporine-treated patients experienced graft loss and 19% (8/42) of cyclosporine-treated patients had died following an episode of BPAR. The overall prevalence of donor-specific antibodies was 6% and 15% for the NULOJIX recommended regimen and cyclosporine, respectively, up to 36 months post-transplant.</p>
<p>The mean GFR following BPAR was 36 mL/min/1.73 m<span class="Sup">2</span> in NULOJIX patients and 24 mL/min/1.73 m<span class="Sup">2</span> in cyclosporine-treated patients at one year. The relationship between BPAR, GFR, and patient and graft survival is unclear due to the limited number of patients who experienced BPAR, differences in renal hemodynamics (and, consequently, GFR) across maintenance <span class="product-label-link" type="condition" conceptid="4242843" conceptname="Immunosuppression">immunosuppression</span> regimens, and the high rate of switching treatment regimens after BPAR.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s14.1.3.2"></a><a name="section-13.1.3.2"></a><p></p>
<h4>Assessment of Efficacy in the EBV Seropositive Subpopulation</h4>
<p class="First">NULOJIX is recommended for use only in EBV seropositive patients [see <span class="Italics"><a href="#s1.2">Indications and Usage (1.2)</a></span>].</p>
<p>In Study 2, approximately 91% of the patients were EBV seropositive prior to transplant. Efficacy results in the EBV seropositive subpopulation were consistent with those in the total population studied.</p>
<p>By one year, the efficacy failure rate in the EBV seropositive population was 29% (45/156) in patients treated with the NULOJIX recommended regimen and 28% (47/168) in patients treated with cyclosporine (difference=0.8%, 97.3% CI [−10.3, 11.9]). Patient and graft survival rate in the EBV seropositive population was 89% (139/156) in the NULOJIX-treated patients and 86% (144/168) in cyclosporine-treated patients (difference=3.4%, 97.3% CI [−4.7, 11.5]).</p>
<p>By three years, efficacy failure was 35% (54/156) in NULOJIX-treated patients and 36% (61/168) in cyclosporine-treated patients. Patient and graft survival was 83% (130/156) in NULOJIX-treated patients compared with 77% (130/168) in cyclosporine-treated patients (difference=5.9%, 97.3% CI [−3.8, 15.6]).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s14.1.3.3"></a><a name="section-13.1.3.3"></a><p></p>
<h4>Assessment of Glomerular Filtration Rate (GFR)</h4>
<p class="First">Glomerular Filtration Rate (GFR) was measured at one and two years and was calculated using the Modification of Diet in <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">Renal Disease</span> (MDRD) formula at one, two, and three years after transplantation. As shown in Table 10, both measured and calculated GFR was higher in patients treated with the NULOJIX recommended regimen compared to patients treated with the cyclosporine control regimen at all time points. As shown in Figure 2, the differences in GFR were apparent in the first month after transplant and were maintained up to three years (36 months). An analysis of change of calculated mean GFR between Month 3 and Month 36 demonstrated a decrease of 0.8 mL/min/year (95% CI [−1.9, 0.3]) for NULOJIX-treated patients and a decrease of 2.0 mL/min/year (95% CI [−3.1, −0.8]) for cyclosporine-treated patients.</p>
<table cellpadding="4.8pt" width="100%">
<caption><span>Table 10: Measured and Calculated GFR for Study 2: Recipients of Extended Criteria Donor Kidneys</span></caption>
<col width="39%">
<col width="23%">
<col width="19%">
<col width="19%">
<thead><tr class="First Last">
<th class="Botrule Lrule Rrule Toprule" align="left" valign="top"><span class="Bold">Parameter</span></th>
<th class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<span class="Bold">NULOJIX</span><br><span class="Bold">Recommended Regimen</span><br><span class="Bold">N=175</span>
</th>
<th class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<span class="Bold">Cyclosporine</span><br><span class="Bold">(CSA)</span><br><span class="Bold">N=184</span>
</th>
<th class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<span class="Bold">NULOJIX-CSA</span><br><br><span class="Bold">(97.3% CI)</span>
</th>
</tr></thead>
<tfoot><tr class="First Last"><td class="Botrule" align="left" colspan="4" valign="top">*  GFR was measured using the <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span>-iothalamate method.<br><span class="Sup">†</span>  Measured GFR was not assessed at Year 3.<br><span class="Sup">‡</span>  GFR was calculated using the MDRD formula.</td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Lrule Rrule Toprule"><p class="First">Measured GFR* mL/min/1.73 m<span class="Sup">2</span> mean (SD)</p></td>
<td class="Lrule Rrule Toprule" align="center"><p class="First"> </p></td>
<td class="Lrule Rrule Toprule" align="center"><p class="First"> </p></td>
<td class="Lrule Rrule Toprule" align="center"><p class="First"> </p></td>
</tr>
<tr>
<td class="Lrule Rrule"><p class="First">Year 1</p></td>
<td class="Lrule Rrule" align="center"><p class="First">49.6 (25.8)</p></td>
<td class="Lrule Rrule" align="center"><p class="First">45.2 (21.1)</p></td>
<td class="Lrule Rrule" align="center"><p class="First">4.3 (−1.5, 10.2)</p></td>
</tr>
<tr>
<td class="Lrule Rrule" align="center"><p class="First"> </p></td>
<td class="Lrule Rrule" align="center"><p class="First">(n=151)</p></td>
<td class="Lrule Rrule" align="center"><p class="First">(n=154)</p></td>
<td class="Lrule Rrule" align="center"><p class="First"> </p></td>
</tr>
<tr>
<td class="Lrule Rrule"><p class="First">Year 2<span class="Sup">†</span></p></td>
<td class="Lrule Rrule" align="center"><p class="First">49.7 (23.7)</p></td>
<td class="Lrule Rrule" align="center"><p class="First">45.0 (27.2)</p></td>
<td class="Lrule Rrule" align="center"><p class="First">4.7 (−1.8, 11.3)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><p class="First"> </p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">(n=139)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">(n=136)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First"> </p></td>
</tr>
<tr>
<td class="Lrule Rrule"><p class="First">Calculated GFR<span class="Sup">‡</span> mL/min/1.73 m<span class="Sup">2</span> mean (SD)</p></td>
<td class="Lrule Rrule" align="center"><p class="First"> </p></td>
<td class="Lrule Rrule" align="center"><p class="First"> </p></td>
<td class="Lrule Rrule" align="center"><p class="First"> </p></td>
</tr>
<tr>
<td class="Lrule Rrule"><p class="First">Year 1</p></td>
<td class="Lrule Rrule" align="center"><p class="First">44.5 (21.8)</p></td>
<td class="Lrule Rrule" align="center"><p class="First">36.5 (21.1)</p></td>
<td class="Lrule Rrule" align="center"><p class="First">8.0 (2.5, 13.4)</p></td>
</tr>
<tr>
<td class="Lrule Rrule" align="center"><p class="First"> </p></td>
<td class="Lrule Rrule" align="center"><p class="First">(n=158)</p></td>
<td class="Lrule Rrule" align="center"><p class="First">(n=159)</p></td>
<td class="Lrule Rrule" align="center"><p class="First"> </p></td>
</tr>
<tr>
<td class="Lrule Rrule"><p class="First">Year 2</p></td>
<td class="Lrule Rrule" align="center"><p class="First">42.8 (24.1)</p></td>
<td class="Lrule Rrule" align="center"><p class="First">34.9 (21.6)</p></td>
<td class="Lrule Rrule" align="center"><p class="First">8.0 (1.9, 14)</p></td>
</tr>
<tr>
<td class="Lrule Rrule" align="center"><p class="First"> </p></td>
<td class="Lrule Rrule" align="center"><p class="First">(n=158)</p></td>
<td class="Lrule Rrule" align="center"><p class="First">(n=154)</p></td>
<td class="Lrule Rrule" align="center"><p class="First"> </p></td>
</tr>
<tr>
<td class="Lrule Rrule"><p class="First">Year 3</p></td>
<td class="Lrule Rrule" align="center"><p class="First">42.2 (25.2)</p></td>
<td class="Lrule Rrule" align="center"><p class="First">31.5 (22.1)</p></td>
<td class="Lrule Rrule" align="center"><p class="First">10.7 (4.3, 17.2)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="center"><p class="First"> </p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">(n=154)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">(n=143)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First"> </p></td>
</tr>
</tbody>
</table>
<p><span class="Bold">Figure 2: Calculated (MDRD) GFR through Month 36; Study 2: Recipients of Extended Criteria Donor Kidneys</span></p>
<div class="Figure">
<a name="id2411"></a><img alt="Figure 2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c16ac648-d5d2-9f7d-8637-e2328572754e&amp;name=figure2.jpg">
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s14.1.3.4"></a><a name="section-13.1.3.4"></a><p></p>
<h4>Assessment of <span class="product-label-link" type="condition" conceptid="4032423" conceptname="Transplant glomerulopathy">Chronic Allograft Nephropathy</span> (CAN)</h4>
<p class="First">The prevalence of <span class="product-label-link" type="condition" conceptid="4032423" conceptname="Transplant glomerulopathy">chronic allograft nephropathy</span> (CAN) at one year, as defined by the Banff ’97 classification system, was 46% (80/174) in patients treated with the NULOJIX recommended regimen and 52% (95/184) of patients treated with the cyclosporine control regimen. CAN was not evaluated after the first year following transplantation. The clinical significance of this finding is unknown.</p>
</div>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="s16"></a><a name="section-14"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">NULOJIX<span class="Sup">®</span> (belatacept) lyophilized powder for intravenous infusion is supplied as a single-use vial with a <span class="Italics"><span class="Underline">silicone-free disposable syringe</span></span> in the following packaging configuration:</p>
<table cellpadding="4.8pt" width="67.12%">
<col width="23%">
<col width="23%">
<col width="31%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="middle"><p class="First"><span class="Bold">Description</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First"><span class="Bold">NDC Number</span></p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">One 250-mg vial</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">One 12 mL Syringe</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">0003-0371-13</p></td>
</tr>
</tbody>
</table>
<div class="Section" data-sectionCode="44425-7">
<a name="s16.1"></a><a name="section-14.1"></a><p></p>
<h2>16.1 Storage</h2>
<p class="First">NULOJIX lyophilized powder is stored refrigerated at 2°-8°C (36°-46°F). Protect NULOJIX from light by storing in the original package until time of use.</p>
<p>The reconstituted solution should be transferred from the vial to the infusion bag or bottle immediately. The NULOJIX infusion must be completed within 24 hours of constitution of the NULOJIX lyophilized powder. If not used immediately, the infusion solution may be stored under refrigeration conditions: 2°-8°C (36°-46°F) and protected from light for up to 24 hours (a maximum of 4 hours of the total 24 hours can be at room temperature: 20°-25°C [68°-77°F] and room light) [see <span class="Italics"><a href="#s2.2">Dosage and Administration (2.2)</a></span>].</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="s17"></a><a name="section-15"></a><p></p>
<h1>17  PATIENT COUNSELING INFORMATION</h1>
<p class="First">Advise the patient to read the FDA-approved patient labeling (Medication Guide).</p>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_029c9531-478b-49f8-a424-138ff36714f7"></a><a name="section-15.1"></a><p></p>
<div class="Section" data-sectionCode="42229-5">
<a name="s17.1"></a><a name="section-15.1.1"></a><p></p>
<h3>Post-Transplant <span class="product-label-link" type="condition" conceptid="4079147" conceptname="Lymphoproliferative disorder">Lymphoproliferative Disorder</span></h3>
<p class="First">The overall risk of PTLD, especially CNS PTLD, was elevated in NULOJIX-treated patients. Instruct patients to immediately report any of the following neurological, cognitive, or behavioral signs and symptoms during and after therapy with NULOJIX [see <span class="Italics"><a href="#s0">Boxed Warning</a></span> and <span class="Italics"><a href="#s5.1">Warnings and Precautions (5.1)</a></span>]:</p>
<dl>
<dt>•</dt>
<dd>changes in mood or usual behavior</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, problems thinking, <span class="product-label-link" type="condition" conceptid="439147" conceptname="Amnesia">loss of memory</span></dd>
<dt>•</dt>
<dd>changes in walking or talking</dd>
<dt>•</dt>
<dd>decreased strength or <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> on one side of the body</dd>
<dt>•</dt>
<dd>changes in vision</dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s17.2"></a><a name="section-15.1.2"></a><p></p>
<h3> Other Malignancies</h3>
<p class="First">Inform patients about the increased risk of malignancies, in addition to PTLD, while taking immunosuppressive therapy, especially skin cancer. Instruct patients to limit exposure to sunlight and UV light by wearing protective clothing and using a sunscreen with a high protection factor. Instruct patients to look for any signs and symptoms of skin cancer, such as suspicious moles or lesions [see <span class="Italics"><a href="#s5.3">Warnings and Precautions (5.3)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s17.3"></a><a name="section-15.1.3"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="433957" conceptname="Progressive multifocal leukoencephalopathy">Progressive Multifocal Leukoencephalopathy</span></h3>
<p class="First">Cases of PML have been reported in NULOJIX-treated patients. Instruct patients to immediately report any of the following neurological, cognitive, or behavioral signs and symptoms during and after therapy with NULOJIX [see <span class="Italics"><a href="#s5.4">Warnings and Precautions (5.4)</a></span>]:</p>
<dl>
<dt>•</dt>
<dd>changes in mood or usual behavior</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, problems thinking, <span class="product-label-link" type="condition" conceptid="439147" conceptname="Amnesia">loss of memory</span></dd>
<dt>•</dt>
<dd>changes in walking or talking</dd>
<dt>•</dt>
<dd>decreased strength or <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> on one side of the body</dd>
<dt>•</dt>
<dd>changes in vision</dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s17.4"></a><a name="section-15.1.4"></a><p></p>
<h3>Other Serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></h3>
<p class="First">Inform patients about the increased risk of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> while taking immunosuppressive therapy. Instruct patients to adhere to antimicrobial prophylaxis regimens as prescribed. Tell patients to immediately report any signs and symptoms of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> during therapy with NULOJIX [see <span class="Italics"><a href="#s5.5">Warnings and Precautions (5.5)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s17.5"></a><a name="section-15.1.5"></a><p></p>
<h3>Immunizations</h3>
<p class="First">Inform patients that vaccinations may be less effective while they are being treated with NULOJIX. Advise patients that live vaccines should be avoided [see <span class="Italics"><a href="#s5.8">Warnings and Precautions (5.8)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s17.6"></a><a name="section-15.1.6"></a><p></p>
<h3>Pregnant Women and Nursing Mothers</h3>
<p class="First">Inform patients that NULOJIX has not been studied in pregnant women or nursing mothers so the effects of NULOJIX on pregnant women or nursing infants are not known. Instruct patients to tell their healthcare provider if they are pregnant, become pregnant, or are thinking about becoming pregnant [see <span class="Italics"><a href="#s8.1">Use in Specific Populations (8.1)</a></span>]. Instruct patients to tell their healthcare provider if they plan to breast-feed their infant [see <span class="Italics"><a href="#s8.3">Use in Specific Populations (8.3)</a></span>].</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_4a2d13fd-66f8-4545-8d5a-0f973e2ff577"></a><a name="section-16"></a><p></p>
<p class="First">Bristol-Myers Squibb Company<br>Princeton, New Jersey 08543<br><br>1274492A2<br>Rev September 2014</p>
</div>
<div class="Section" data-sectionCode="42231-1">
<a name="ID_5560450f-73d2-4031-9606-26f276740b9a"></a><a name="section-17"></a><p></p>
<h1>MEDICATION GUIDE<br><span class="Bold">NULOJIX<span class="Sup">®</span> (noo-LOJ-jiks)</span><br><span class="Bold">(belatacept)</span><br><span class="Bold">For Injection, For Intravenous Use</span>
</h1>
<p class="First">Read this Medication Guide before you start receiving NULOJIX and before each treatment. There may be new information. This Medication Guide does not take the place of talking with your doctor about your medical condition or your treatment.</p>
<p><span class="Bold">What is the most important information I should know about NULOJIX?</span></p>
<p><span class="Bold">NULOJIX increases your risk of serious side effects, including:</span></p>
<dl>
<dt>•</dt>
<dd>
<span class="Bold">Post-transplant <span class="product-label-link" type="condition" conceptid="4079147" conceptname="Lymphoproliferative disorder">lymphoproliferative disorder</span> (PTLD).</span> PTLD is a condition that can happen if certain white blood cells grow out of control after an organ transplant because your immune system is weak. PTLD can get worse and become a type of cancer. PTLD can lead to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.<br>People treated with NULOJIX have a higher risk of getting PTLD. If you get PTLD with NULOJIX you are at especially high risk of getting it in your brain. Your risk for PTLD is also higher if you:<dl>
<dt>•</dt>
<dd>have never been exposed to the Epstein-Barr virus (EBV). Your doctor should test you for EBV. Do not receive NULOJIX unless you are EBV positive (you have been exposed to EBV).</dd>
<dt>•</dt>
<dd>get an <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> with a virus called cytomegalovirus (CMV).</dd>
<dt>•</dt>
<dd>receive treatment for <span class="product-label-link" type="condition" conceptid="4248020" conceptname="Graft rejection">transplant rejection</span> that lowers certain white blood cells called T <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span>.</dd>
</dl>
</dd>
<dt>•</dt>
<dd>
<span class="Bold">Increased risk of getting cancers other than PTLD.</span> People who take medicines that weaken the immune system, including NULOJIX, have a higher risk of getting other cancers, including skin cancer. Talk to your doctor about your risk for cancer. See "<span class="Bold">What should I avoid while receiving NULOJIX?</span>"</dd>
<dt>•</dt>
<dd>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="433957" conceptname="Progressive multifocal leukoencephalopathy">Progressive multifocal leukoencephalopathy</span> (PML).</span> PML is a rare, serious brain <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> caused by JC virus. People with weakened immune systems are at risk for getting PML. PML can result in <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> or severe <span class="product-label-link" type="condition" conceptid="4052648" conceptname="Disability">disability</span>. There is no known prevention, treatment, or cure for PML.</dd>
<dt>•</dt>
<dd>
<span class="Bold">Increased risk of getting other serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, including <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> (TB) and other <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> caused by bacteria, viruses, or fungi.</span> These serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> may lead to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Also, a virus called BK virus can affect how your kidney works and cause your transplanted kidney to fail.</dd>
</dl>
<p><span class="Bold">Tell your doctor right away if you get any of the following symptoms during treatment with NULOJIX:</span></p>
<dl>
<dt>•</dt>
<dd>change in mood or your usual behavior</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span> or problems thinking or with memory</dd>
<dt>•</dt>
<dd>change in the way you walk or talk</dd>
<dt>•</dt>
<dd>decreased strength or <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> on one side of your body</dd>
<dt>•</dt>
<dd>change in vision</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4181178" conceptname="Night sweats">night sweats</span>, or <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">tiredness</span> that does not go away</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span></dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="315085" conceptname="Lymphadenopathy">swollen glands</span></dd>
<dt>•</dt>
<dd>flu, <span class="product-label-link" type="condition" conceptid="4197268" conceptname="Nasopharyngitis">cold symptoms</span>, or <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span></dd>
<dt>•</dt>
<dd>stomach-area <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span></dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> or <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span></dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span> over your transplanted kidney</dd>
<dt>•</dt>
<dd>change in the amount of urine that you make, blood in your urine, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> or burning on urination</dd>
<dt>•</dt>
<dd>a new <span class="product-label-link" type="condition" conceptid="4316083" conceptname="Skin lesion">skin lesion</span> or bump, or change in size or color of a mole</dd>
</dl>
<p>See "<span class="Bold">What are the possible side effects of NULOJIX?</span>" for more information about side effects.</p>
<p>Liver transplant patients should not receive NULOJIX because of an increased risk of losing the transplanted liver (graft loss) and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Talk to your doctor if you would like more information about this risk.</p>
<p><span class="Bold">What is NULOJIX?</span></p>
<p>NULOJIX is a prescription medicine used in adults to prevent <span class="product-label-link" type="condition" conceptid="4248020" conceptname="Graft rejection">transplant rejection</span> in people who have received a kidney transplant. <span class="product-label-link" type="condition" conceptid="4248020" conceptname="Graft rejection">Transplant rejection</span> happens when the body’s immune system senses that the new transplanted kidney is different or foreign, and attacks it. NULOJIX is used with corticosteroids and certain other medicines to help prevent rejection of your new kidney.</p>
<p>It is not known if NULOJIX is safe and effective in children under 18 years of age.</p>
<p>NULOJIX is only used in people who have been exposed to the EBV virus.</p>
<p>It is not known if NULOJIX is safe and effective in people who receive an organ transplant other than a kidney transplant.</p>
<p><span class="Bold">Who should not receive NULOJIX?</span></p>
<p>Do not receive treatment with NULOJIX if you are EBV negative. Your doctor will do a test to see if you were exposed to EBV in the past.</p>
<p><span class="Bold">What should I tell my doctor before receiving NULOJIX?</span></p>
<p>Before receiving NULOJIX, tell your doctor if you:</p>
<dl>
<dt>•</dt>
<dd>plan to receive any vaccines. Talk to your doctor about which vaccines are safe for you to receive during your treatment with NULOJIX. See “<span class="Bold">What should I avoid while receiving NULOJIX?</span>?</dd>
<dt>•</dt>
<dd>have any other medical conditions</dd>
<dt>•</dt>
<dd>are pregnant or plan to become pregnant. It is not known if NULOJIX will harm your unborn baby. If you become pregnant while taking NULOJIX:<dl>
<dt>•</dt>
<dd>
<span class="Bold">Tell your doctor right away.</span> You and your doctor should decide if you will keep receiving NULOJIX while you are pregnant.</dd>
<dt>•</dt>
<dd>Talk with your doctor about enrolling in the National Transplant Pregnancy Registry (NTPR). This Registry collects information about pregnancies in women who have received NULOJIX or if their partner has received NULOJIX, and had a transplant. You can also enroll by calling 1-877-955-6877.</dd>
</dl>
</dd>
<dt>•</dt>
<dd>are breast-feeding or plan to breast-feed. It is not known if NULOJIX passes into your breast milk. You and your doctor should decide if you will receive NULOJIX or breast-feed. You should not do both.</dd>
</dl>
<p><span class="Bold">Tell your doctor about all of the medicines you take</span>, including prescription and non-prescription medicines, vitamins, and herbal supplements.</p>
<p>Know the medicines you take. Keep a list of them to show your doctor and pharmacist when you get a new medicine. Do not take any new medicine without talking with your transplant doctor first.</p>
<p><span class="Bold">How will I receive NULOJIX?</span></p>
<dl>
<dt>•</dt>
<dd>To help prevent rejection of your new kidney, you will receive NULOJIX regularly as prescribed by your doctor. It is important for you to keep all your appointments for NULOJIX treatment and follow up.</dd>
<dt>•</dt>
<dd>You will receive NULOJIX as an intravenous (IV) infusion in your arm. Each IV infusion takes about 30 minutes.</dd>
<dt>•</dt>
<dd>During treatment with NULOJIX, your doctor will test your blood and urine to check how your kidney is working.</dd>
<dt>•</dt>
<dd>Take all the medicines prescribed by your doctor to prevent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> or <span class="product-label-link" type="condition" conceptid="4248020" conceptname="Graft rejection">transplant rejection</span>. Take them exactly as your doctor tells you. Talk to your doctor or pharmacist if you have any questions about how to take your medicines.</dd>
</dl>
<p><span class="Bold">What should I avoid while receiving NULOJIX?</span></p>
<dl>
<dt>•</dt>
<dd>Limit the amount of time you spend in sunlight. Avoid using tanning beds or sunlamps. People who take medicines that weaken the immune system, including NULOJIX, have a higher risk of getting cancer, including skin cancer. Wear protective clothing and use sunscreen with a high protection factor (SPF) when you have to be in the sun.</dd>
<dt>•</dt>
<dd>
<span class="Bold">Avoid receiving live vaccines during treatment with NULOJIX.</span> Talk to your doctor to find out which vaccines are safe for you during this time. Some vaccines may not work as well while you are receiving NULOJIX. See “<span class="Bold">What should I tell my doctor before receiving NULOJIX?</span>?</dd>
</dl>
<p><span class="Bold">What are the possible side effects of NULOJIX?</span></p>
<p>NULOJIX increases your risk of serious side effects that can cause <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. See "<span class="Bold">What is the most important information I should know about NULOJIX?</span>"</p>
<p>Common side effects of NULOJIX include:</p>
<dl>
<dt>•</dt>
<dd>low red blood count (<span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>)</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span></dd>
<dt>•</dt>
<dd>kidney or <span class="product-label-link" type="condition" conceptid="195588" conceptname="Cystitis">bladder infection</span></dd>
<dt>•</dt>
<dd>swollen legs, feet, or ankles</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span></dd>
<dt>•</dt>
<dd>high blood pressure</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span></dd>
<dt>•</dt>
<dd>new kidney not working well</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span></dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span></dd>
<dt>•</dt>
<dd>low potassium or high potassium in your blood</dd>
<dt>•</dt>
<dd>low white blood cell count</dd>
</dl>
<p>Tell your doctor about any side effect that bothers you or that does not go away. These are not all the possible side effects of NULOJIX. For more information, ask your doctor or pharmacist.</p>
<p><span class="Bold">Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</span></p>
<p><span class="Bold">You may also report side effects to BMS at 1-800-321-1335.</span></p>
<p><span class="Bold">General information about NULOJIX</span></p>
<p>Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. This Medication Guide summarizes the most important information about NULOJIX. If you would like more information about NULOJIX, talk with your doctor. You can ask your pharmacist or doctor for information about NULOJIX that is written for healthcare professionals.</p>
<p>For more information, go to www.NULOJIX.com or call 1-800-321-1335.</p>
<p><span class="Bold">What are the ingredients in NULOJIX?</span></p>
<p><span class="Bold">Active ingredient:</span> belatacept</p>
<p><span class="Bold">Inactive ingredients:</span> monobasic sodium phosphate, sodium chloride, and sucrose</p>
<p>This Medication Guide has been approved by the U.S. Food and Drug Administration.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s23"></a><a name="section-18"></a><p></p>
<p class="First"><br><br><br>Bristol-Myers Squibb Company<br>Princeton, New Jersey 08543<br><br><br>1274492A2 / 1275358A2<br>Rev September 2014</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_87a17964-26dc-4067-8ea2-2f249c0ca870"></a><a name="section-19"></a><p></p>
<h1>NULOJIX 250 mg per vial Representative Packaging</h1>
<p class="First">See <span class="Bold">How Supplied</span> section for a complete list of available packages of NULOJIX.</p>
<p><span class="Bold">Contains 1 Vial and 1 Syringe</span><br><span class="Bold">NDC 0003-0371-13 </span><br><span class="Bold">Nulojix<span class="Sup">®</span></span><br>(belatacept)<br>Rx only<br><span class="Bold">For Injection</span><br><span class="Bold">For Intravenous Infusion</span><br><span class="Bold">250 mg per vial</span><br><span class="Bold">ONLY USE THE SILICONE-FREE DISPOSABLE SYRINGE INCLUDED IN THIS PACKAGE FOR RECONSTITUTION</span><br><span class="Bold">Pre-Infusion Checklist enclosed.</span><br><span class="Bold">Provide enclosed Medication Guide to the patient.</span><br><span class="Bold">1-888-NULOJIX</span><br><span class="Bold">www.nulojix.com</span><br>Bristol-Myers Squibb</p>
<div class="Figure">
<a name="id3622773"></a><img alt="Nulojix 250 mg Vial Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c16ac648-d5d2-9f7d-8637-e2328572754e&amp;name=nulojix-250mgvial-carton.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>NULOJIX 		
					</strong><br><span class="contentTableReg">belatacept injection, powder, lyophilized, for solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0003-0371</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>belatacept</strong> (belatacept) </td>
<td class="formItem">belatacept</td>
<td class="formItem">250 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sodium phosphate, monobasic</strong></td>
<td class="formItem">34.5 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>sodium chloride</strong></td>
<td class="formItem">5.8 mg</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sucrose</strong></td>
<td class="formItem">500 mg</td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0003-0371-13</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem">06/15/2011</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">1  in 1 VIAL, SINGLE-USE; Combination Product Type = C102834</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">BLA</td>
<td class="formItem">BLA125288</td>
<td class="formItem">06/15/2011</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>E.R. Squibb &amp; Sons, L.L.C.
							(011550092)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 9/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>1834cca2-134c-44bb-9d96-f517fc5e4e82</div>
<div>Set id: c16ac648-d5d2-9f7d-8637-e2328572754e</div>
<div>Version: 5</div>
<div>Effective Time: 20140930</div>
</div>
</div> <div class="DistributorName">E.R. Squibb &amp; Sons, L.L.C.</div></p>
</body></html>
